vaccine-preventable subject free possible current such assert subsequent additional digital re-hosted educational non-commercial computer-extracted Computer-extracted such unusual odd Original 2021-11-05 Vaccine-Preventable Vaccine-Preventable responsible additional available major top effective first 1886-1963 French diphthe- critical numerous includ- 1897-1985 successful Vaccine-Preventable commercial responsible current other “ Vaccine-Preventable Other bacterial live human influenzae bacterial whole-cell toxoid viral human Secular oral global Other Last indigenous Last wild civilian A-21 B-1 B-5 B-7 B-14 mococcal otavte Vaccine-Preventable 20th avaialble //www.cdc.gov/vaccines/vac-gen/shortages/default.htm inactivated inactivated generic inactivated human acellular acellular acellular acellular acellular acellular acellular 10-64 acellular 11-64 immune Japanese quadrivalent quadrivalent quadrivalent 13-valent 23-valent inactivated multi-dose vial single-dose single-dose vial single-dose vial single-dose single-dose vial single-dose single-dose vial single-dose 15-dose vial single-dose single-dose vial 10-dose vial 15-dose vial single-dose single-dose vial single-dose vial single-dose vial single-dose vial single-dose single-dose single-dose single-dose vial single-dose vial vial single-dose neonatal single-dose vial single-dose single-dose single-dose multiple single-use single-dose single-dose vial single-dose vial single-dose vial single-dose vial single-dose vial single-dose vial single-dose 5-dose vial single-dose 10-dose vial single-dose vial single-dose vial human human inactivated multiple pasteur vial human human live oral live oral live oral immune single-dose single-dose single-dose 20-dose vial 4-capsule single-dose vial 25-U vial 5-dose vial single-dose vial live human live Vaccine-Preventable detailed basic useful Many available additional indigenous foreign discriminatory infectious most foreign gener- specific single basic active infectious specific single own permanent human human tive few own complex primary foreign “ such immune specific cell-mediated foreign immune effective live alive infec- such Other such long certain effective good other common other Passive protec- temporary common trans- last full-term same certain red small intravenous immune large human human major human homologous homologous human heterologous human many different many different certain congenital immuno- high high other lesser several available immune human polyclonal many different single monoclonal single many certain colorectal ovarian chronic lymphocytic non-Hodgkin infectious single specific single certain infectious monoclonal available preven- syncytial mono- specific other live live antigen-specific cellular passive temporary active many similar natural active disease-causing general infectious many certain many active similar natural potential similar natural maternal such nutritional basic live different viral bacterial available live available protein-based whole protein-based polysaccharide-based Protein-based bacterial Most polysaccharide-based polysaccharide-based more similar immune wild effective similar natural wild attenu- serial immune small immune live ineffective such wild much natural adverse live virtu- identical natural wild small live such second severe fatal immunodefi- certain human possible original disease-causing live oral transpla- poor sensitive yellow oral available viral same higher yellow live available bacterial available oral oral available live 3-5 humoral fractional polysac- alive entire live present antibody-containing general protective protective second third natural humoral cellular periodic supplemental available acellular available inactivated whole viral whole whole available available pneumococcal meningococcal certain available pneumococcal meningococcal available pneumococcal independent able T-cell-independent immunogenic younger immunogenic younger functional inactivated polysaccharide functional polysaccharide little late independent pneumococcal meningococcal genetic available human respective viral influenza vaccine-induced thorough common current familiar important appropriate Specific immu- antibody-containing live simultaneous nonsimulta- neous different subsequent same same certain such live live injectable enough viral live necessary least incuba- necessary necessary antibody-containing varicella- live antibody-containing few significant low anti-Rho other last possible necessary live antibody-containing antibody-containing Negligible syncytial young red negligible -negligible same other Simultaneous same live decreased adverse eligible important appropriate early unvaccinated vaccine-eligible same indicated same individual same sanofi-pasteur same additional taneous single patient separate live Nonsimultaneous same live same live parenteral same less second effective serologic sero- less single-antigen yellow 1-27 other live parenteral live second oral oral oral other other older oral available likely same live live oral oral oral live other inactivated live other youngest multidose more adequate same optimal minimal multidose necessary up-to-date international minimum minimum minimum minimum minimal minimal first younger older second few minimum unlikely negative recommended reliable preferable reliable preferable minimum valid 4-day minimum valid invalid least equal certain local specific super- 4-day valid minimum scheduled next available recom- necessary oral typhoid oral Available extended significant final necessary live recommended additional small first single second immune second “ live long-lasting necessary recommended protective second third few notable periodic additional rare older extraneous active specific adverse extraneous primary adverse medical adverse true adverse further true adverse general local systemic least severe frequent least frequent common self-limited common adverse local such Local common such Local few mild self-limited rare local severe due high many unrelated adverse generalized common unre- concurrent viral excessive adverse frequent systemic adverse common acellular adverse live such viral similar mild natural mild occur 7-21 mucous nose upper due rare third severe anaphy- other such preservative antibiotic bacterial allergic life-threatening allergic mini- good prior public private significant adverse significant adverse serious adverse Most temporary serious adverse adverse true serious general adverse similar serious such passive less general present adverse high acel- lular pediatric high adverse few true severe anaphylactic due identifiable contraindica- severe allergic encephalopathy due identifiable severe further pediatric pertussis-containing higher shock-like hypotonic inconsolable more vaccina- temporary vaccina- live temporary severe recent antibody-containing severe anaphylactic allergic subsequent medical typical anaphylactic rare table allergic such animal antibiotic preservative common yellow anaphylactic anaphylactic-like adverse reasonable yellow Several recent severe severe contraindica- Egg-allergic prior anaphylactic neomycin manifes- delayed-type cell-mediated delayed-type commercial responsible allergic natural dry natural natural natural same lesser medical other natural vial intravascular synthetic medical vial synthetic natural natural allergic common contact-type latex-containing injection-procedure- diabetic anaphylactic natural other anaphylactic dry natural natural pregnant infec- theoretical fetal theoretical pregnant general pregnant fetal general pregnant human pregnant pregnant influ- pregnant single pregnant single pregnant certain such protec- pregnant certain such preg- second third coincidental spontaneous common first pregnant adoles- catch-up inci- high pregnant younger other vulnerable Susceptible pregnant eligible isolated safe severe due uncontrolled isolated safe immunosuppressed significant immunosup- congenital live same least large more prednisone more weight longer nosuppressed such alternate-day short less high-dose topical more alternate-day short topical live human immune therapeutic monoclonal other opportunistic live live least pressed vaccine-preventable invasive pneumococcal invasive meningococcal invasive poor immunosuppres- functional immunosuppressed human immuno- general same recommenda- other severe clinical asymptomatic severe other symptomatic adequate eligible hema- topoietic neoplastic immunode- own autologous other transplant 1-4 autologous pneumococcal 6-12 post-transplant vaccine-preventable 1-4 alloge- autologous certain vaccine- preventable early additional other healthcare vaccinated adverse severe live certain true Such invalid common invalid contra- mild preg- anaphylactic certain anaphylactic adverse mild such low-grade upper Several large young mild Low-grade necessary immu- overall arbitrary oral other least antibacte- rial antimicrobial live-virus antiviral antiviral active active famci- administra- possible ill adverse critical healthy healthy live pregnant immunosuppressed noncom- municable human common older other yellow high passive preventable maternal human rare eligible unknown low low hepa- chronological initial gestational likely older larger preterm unknown immuno- maternal unknown maternal positive less initial additional less HBsAg-negative first chronological available such true anaphylactic severe adverse sudden Varicella-containing hereditary immuno- first-degree potential same poten- false-negative same more most least routine available such available prudent new interferon-gamma previous previous diagnostic previous other live same same eligible critical high same other serious adverse difficult few ques- serious such other acute adverse severe such vacci- other X-ray past pregnant next anaphylactic such previous further efficient generic Most familiar minor allergic medical serious anaphylactic previous pertussis-containing continuous higher previous other adverse future present local unstable progressive stable neurologic usual such other live asymptomatic severe immunosuppres- other x-ray treat- Live-virus long-term high-dose past live immune pregnant next Live-virus theoretical active young careful theoretical endemic-disease immediate second third past live injectable live-virus vari- yellow live same live available assis- passive Red American immuniza- recom- admin- important public safe efficacious 13:394-407 hematopoietic 44:521-6 important appropriate essential high own Vaccine-preventable low wild-type immuni- vaccine-preventable low vaccina- several possible new suboptimal immu- sustainable crucial vaccine-preventable unprotected other such severe social economic physical many ultimate late immu- further suboptimal other lower older pneumococcal racial Low-income greater underim- low important fewer consistent older optimal least Sustainable High one-time short-term immuni- necessary effective such other strate- specific such low successful current most sufficient least unvaccinated up-to-date necessary high other low knowledgeable capable new public private diagnostic high public private governmental nongovernmental medical other specific effective high sustainable specific measurable Second key governmental personal Much personal personal critical medical potential medical essential several most healthcare accurate own actual situa- flexible defined assess- necessary necessary appropriate representative appropriate next second same summary specific substantial effective personal critical sufficient high desirable variable effective single different different small longer-term new other other possible immuniza- diverse final more own other strate- successful other knowledgeable appropriate statistical individual educational other such informal local govern- professional actual such electronic different face- to-face e-mail last several public private Many federal other available periodic possible single overall single more private large private electronic previous previous basic individual various potential such specific such available //www.cdc.gov/vaccines/programs/cocasa/ available effective gradual consistent private substantial median up-to-date public private public private adult immuniza- annual widespread powerful Other substantial certain other immuni- complementary favorable available vital medical electronic critical applicable legal such available inspec- easy easy -reflect current active medical up-to- new necessary complete accurate School-based public quick such important new alternative available patient population-based computerized geographic complete medical single reliable enrolled recom- strong effective such public vaccine-preventable younger operational population-based immuniza- age-group local public key federal available -verbal powerful recom- pediatric likely reluctant likely positive true many necessary useful next additional higher due due vary effective due due personaliza- effective various implemen- available computer-generated weekly other preventive other aggressive overdue local technical public private due due different overall due due computer-generated due such “ older nurse continual eligible eligible Missed several many simul- taneous injectable immune adverse scientific available Missed simultaneous additional larger well-child Other large institutional bureaucratic such reim- acute-care opportu- Several many different Missed • nonphysi- cian direct such other interven- positive responsible knowledgeable responsible higher general available professional greater effective other knowledgeable valid additional appropriate immuniza- • unknown physical psychological such specific such clinic many possible knowledgeable such eligible important clinic appoint- such interpersonal reliable direct supportive encouraging assis- American provider-based American high public public 277:631-635 clinic underimmunized cost-effective underimmunized 101:690-691 private 112:958-63 preventive prime public manufac- general such potential specific significant public pharmaceutical safe effec- adverse minor self-limited rare serious key active critical healthy lower rare vaccine-preventable potential vaccine-preventable adequate same adverse true adverse likely adverse vaccine-preventable public potential public critical epidemic several other similar willing vaccine adverse true unrelated public higher other medical pharmaceutical healthy healthy healthy substan- lower possible rare adverse public many local widespread potential large universal human-directed strict regulatory dynamic necessary adjust oral global actual global continuous immu- other pharmaceutical undergo human clinical clinical serious few last last several few several already-licensed adverse serious safe effective every- clinical manu- rigorous potential outweigh common such injection-site small rare many largest inadequate potential possible rare essential vaccine-associated adverse public assur- public own public rare critical unusual rare particular high certain possible current Large-Linked public possible rare large-linked rare specific immu- volun- long-term unanswered clinical individual certain adverse specific national adverse passive general local unpub- large small additional significant medical certain significant adverse other local adverse Serious adverse life-threatening permanent serious addi- tional medical full possible serious follow-up strict able primary new rare adverse patient particular adverse early public rare patient personal available common rare local systemic intrinsic adminis- adverse intrinsic individual vaccine-associated paralytic oral technical due natural More adverse plausible adverse specific clinical strong anaphylaxis natural positive clinical greater specific unvaccinated other scientific rare large medical medical new large medical new active real possible more personal available individual adverse better recent scientific indi- vidual certain adverse such right similar regional complex clinical vaccine individual infor- other critical longer young military unique active medical military active inves- potential adverse military military civilian important new military such pandemic such yellow Japanese specific specific potential vaccine-associated autoimmune prominent mid- whole-cell scientific many vaccine public epidemic certain adverse rebuttable preponderant current serious certain swift informa- available rare adverse available www.hrsa.gov/ govern- new certain pandemic serious adverse pandemic pandemic clinical such serious certain More • -vaccine federal immuniza- key proper contraindica- avail- able other possible immuniza- Other cold oldest prior same administra- corrective available available important appropriate optimal same specific minimum same important effective greater such pediatric careful patient sched- extra serious adverse serious adverse general present adverse Most temporary individual allergic American adverse serious adverse most local prior minor upper respira- low-grade local moderate prior antimicrobial infectious best clinical vaccine anaphylactic available familiar cardiopulmonary -vaccine certain adverse adverse reportable available //vaers.hhs.gov/ unable one-page // 877-721-0366 valuable ongoing rare legal understandable medical public private available responsible other available certain few certain religious personal basic effective imperative specific extensive up-to-date public private available multiple factual appropriate empathetic essential misinforma- Other available //www.cdc.gov/ effective public common key unimmunized unim- certain potential vaccine-preventable unimmunized update critical American Red American 457-460 Current permanent 1991-2001 current chal- new 599-606 human recombinant 287-294 2009- available available few important appropriate vaccine-preventable attributable wasted patient proper good vaccine-preventable due patient temperature-controlled few best full temperature-controlled affected out-of-range cumulative negative good multiple varicella-containing frozen recom- frozen same average live typhoid instruc- specific varicella-containing varicella-containing varicella-containing available routine appropriate adequate routine such accessible appropriate local long-term adequate available good current safe difficult natural improper due other individual local immu- appropriate poten- responsible least primary desig- primary least vaccine proper ship- least proper least twice daily physical daily physical s potential appropriate potential proper adequate new temporary new familiar available new temporary essential new particular good general specific specific serial routine good serial such contact correct costly inadvertent adminis- available many different stand- commercial pharmaceutical vaccine own exterior ther- able large largest frost- free automatic separate • frost-free automatic own exterior largest good top allow least 1-2 essential proper well-ventilated top least least vaccine dormitory-style dormitory-style small exterior dorm-style dormitory-style unacceptable Dormitory-style external permanent temporary small non-varicella-containing incapable frozen main clinic overnight dormi- bar-style temporary compact dormitory-style digital bio-safe continuous graphic critical good own digital bio-safe continuous minimum/maximum second necessary many expensive vital least tempera- important new potential least continuous auto- recommenda- manual least twice continuous fail automatic electronic undetected unresolved sole necessary cold short inevitable manual electronic open important various consistent particular hot reliable stable recommended individual immu- original same light big able original ready administra- same other uncovered confu- unnecessary corresponding wrong same feasible corresponding helpful pediatric wrong wrong next other e.g proper good several wall multi- multi-strip safety-lock after-hour large helpful vaccine electrical same prin- frozen stable frequent stable extra frozen extra much deli other same same immediate corrective physical original clinic easy appropriate stable such cold other same lower contami- important important immediate important short-term outside frozen other available monthly monthly available current such • shortest normal important shortest specific multidose normal appear- first informa- important important other proper sure cold possible adverse cold other proper specific off-site clinic acceptable critical different general available multidose off-site same different equal same direct frozen trans- refrigerated varicella-containing dry varicella-containing off-site continuous • • Varicella-containing refrozen Varicella-Containing Off-Site varicella-containing off-site Varicella-containing fragile off-site continuous Varicella-containing acceptable other Off-Site appropriate much possible recom- difficult Other possible bacterial such single-dose other immediate particular few more single best clinic bacterial clinic manufacturer-supplied large such administra- needle sterile clinic manufacturer-supplied large needle ready unused clinic returnable certain returnable specific returnable medical unused due unused medical individual available more avail- able RR-2 23-27 //www.cdc.gov/vaccines/pubs/ ACIP-list.htm ucm093830.htm Dormitory-Style //www.nist.gov/manuscript-publication- toxin-mediated diphtheritic • aerobic gram-positive specific genetic severe gram-positive normal diphtheroid other severe toxigenic responsible local responsible major low thrombocy- Clinical severe toxigenic inadequate 2-5 1-10 • 2-5 1-10 mucous -cutaneous -ocular mucous clinical anterior indistinguishable common blood-tinged white mild apparent poor systemic antibiotic exudative 2-3 high common substantial systemic insidious low-grade bluish-white small soft greyish-green black minimal forcible Extensive severe rapid high severe submandibular anterior lymphadenopathy characteristic cutaneous common responsible high natural other recent nontoxigenic less other toxigenic Other mucous vulvovaginal external attributable local attributable local common abnormal cardiac early fatal soft frequent third fifth diaphragmatic Other due higher younger older little last clinical imperative presump- tive critical tonsillar selective hemo- lytic helpful clinical multiple club-shaped Other direct clinical diagnostic antibiotic positive presumptive low nonprotective commercial several available available anti- adequate provisional clinical appropriate maximum less contagious insti- tuted consecutive negative antibiotics-benzathine younger old old older 7- 10-day oral cutaneous nontoxigenic clinical highest highest inci- significant geographic asymptomatic several asymptomatic high present variable less more Effective antibiotic 1940-2009 major top younger rapid widespread high cutaneous nontoxigenic cutaneous most lower socio- economic older older Most unimmunized immunized current inadequate many protective 1980-2004 rare endemic 5-14 15-24 25-39 40-64 classic other major former More entire epidemic due several routine immu- early early toxigenic liquid 7-8 5-12.5 pediatric older available available pediatric acellular available Pediatric similar younger pediatric older pediatric available-Boostrix primary protective greater clinical acellular usual second third fourth third less first first younger older primary valid younger old first older first third second primary fourth fourth fifth recom- fourth fourth 11-12 optimal last first dose next frequent local adverse primary unvaccinated older primary least third dose second single unvaccinated older recommended subsequent active severe allergic anaphy- prior additional severe minor additional severe common self-limited palpable several other systemic common systemic common local local occasion- diphtheria- tetanus-containing extensive painful high severe local severe systemic such urti- neurologic diphtheria-toxoid-containing 20-8°C neous toxigenic appropriate preliminary clinical presumptive strict least negative close other oral close nasal antibiotic fewer unknown immediate primary current more diphtheria toxoid-containing recent Other younger adequate antibiotic addi- tional 10-day other preventive acellular young acellular acellular due diphthe- former pandemic 4:539-50 5th severe clinical secondary unencap- sulated capsular cerebrospinal effective bacterial other invasive bacterial younger invasive younger younger influenzae gram-negative aerobic facultative gram-negative different a-f responsible distinct capsular invasive several asymptomatic distant upper normal common unencapsulated frequent human invasive unknown upper likely striking age-dependent common capsular protective invasive purified long-term invasive anticapsular age-specific asymptomatic small common antigenic so-called anticapsular other genetic important genetic unknown single genetic immune convinc- many organ common invasive common clinical invasive other other neurologic appro- antimicrobial life-threatening neurologic appropriate antimicrobial mild focal severe common invasive common invasive due nontypeable unencapsulated invasive rare serious common small gram-negative invasive pleural middle appropriate positive important younger vaccine labora- antimicrobial viable available rapid sensitive specific capsular negative false-positive similar agglutina- sensitive difficult effective Ampicillin-resistant common invasive effective third- Ampicillin-resistant common life-threatening etiologic initial asymptomatic reser- higher primary seasonal second contagious invasive certain particu- close institutional direct secondary reportable Serotype-specific incomplete 1990-2009 national several active invasive invasive younger invasive Three-hundred due vaccinated unvaccinated 0-1 12-13 24-25 age-dependent invasive 6-11 older invasive recent vaccinated younger invasive younger young three-dose primary Fifty-six eligible primary age-eligible fewer unknown more younger invasive due unknown actual unvaccinated nated socioeconomic large house- low socioeconomic low parental school-aged African socioeconomic younger maternal 1-60 invasive secondary 600-fold higher general younger older secondary first second third fourth secondary transmis- Most low secondary 1985-1988 effective younger older variable effective younger older negative greater available similar other polysaccharide pneumococcal meningococcal typical T-independent age-dependent poor younger minimal immunogenic younger functional polysac- ineffective effective T-independent T-dependent young class-specific useful young available avail- able young third last older different available protec- tive primary uncommon invasive such sickle-cell invasive primary separate primary primary three-dose primary primary ACIP-Recommended 12-15 last older primary minimum least previous interval second third simulta- other primary immunologic subsequent subsequent younger interchangeable protective different third primary primary entire current 15-59 older full current 2-6 12-15 dose 2-6 * 7-11 12-15 last older least previous dose 12-15 least last least last unvaccinated single least last least single up-to-date three- four-dose catch-up child- invasive protective anti-PRP invasive susceptible possible invasive general older older immune asymptomatic infec- invasive functional anatomic sickle immuno- unvaccinated older least pediatric older high-risk available sanofi third available positive unknown immune younger 0-1-6- positive chronic same adequate off-label positive unknown same individual particular third older least second sanofi older prior valid specific available other specific severe allergic moderate severe upper younger immunologic allergic severe younger same individual compo- Adverse common 12-24 such rare serious adverse reportable healthcare invasive local American Red American invasive disap- vaccine-preventable older influenzae invasive 58:1008-9 preventable first epidemic military infectious definitive other non-B primary hygienic passive immune long-term widespread susceptible natural several nonhuman stable stable low moderate higher • natural low higher chlorine fecal-oral transmis- present biliary present several clinical Most infected third longer • • 10-12 15-50 specific symptomatic asymptomatic symptomatic clinical indistinguishable other acute viral abrupt abdominal last symptomatic younger asymptomatic older symptomatic fulminant fulminant higher older older substantial medical ill direct indirect pediatric annual other viral clinical detectable early detectable anti-HAV infec- present total anti-HAV total anti-HAV positive anti-HAV negative such viral helpful investi- molecular specific infec- supportive natural animal chronic fecal-oral person-to-person present illness trans- rare present sewage-contaminated treated appreciable seasonal likely highest minimal personal sexual recent international Injection-drug Forty-five Other international illegal occupational solvent/ detergent-treated noteworthy critical foodborne nosocomial rare neonatal intensive fecal developmental high fewer institutional- ized sporadic common common work-related available important asymptomatic unrecognized other large last high reportable distinct largest under- symptomatic low 1966-2009 highest early hepa- similar 1990-2004 total anti-HAV general 6- older Anti-HAV highest Anti-HAV higher western other western Many high-incidence late similar 1990-2004 such high-rate intermediate-rate last several substantial high few older well-defined certain religious high-rate high first-dose young subsequent clinical other viral hepa- clinical serologic necessary clinical discrete positive whole -pediatric available culture-adapted human preservative 2-phenoxyathanol available pediatric pediatric older seropositive protective single seropositive clinical protective effective clinical clinical high clinical high long-term immune current available kinetic protective Other cellular long-term unknown deter- international other little 12-23 routine successful high routine older average annual higher least routine average annual more less routine older successful high routine vacci- available single pediatric older 6-12 6-12 initial subsequent initial available pediatric pediatric formula- older first 6-18 6-18 initial subsequent initial different interchangeable same preferable available acceptable first first pediatric pediatric first necessary first pediatric older equivalent pediatric equivalent three-dose long-term first second least second third least older first equivalent same single-antigen older least second single-antigen formu- 18-year-old same pediatric older high healthy younger single admin- adequate older chronic immune same separate different anatomic single prolonged international high intermediate illegal occupational close personal regular babysit- international high first 2-dose more Other other illegal occupational occupational A-infected other due occupational Susceptible Susceptible solid sewer routine vaccina- local recommended local older lifelong past such higher negative likeli- indicated low prevac- cost-effective extensive geographic high older certain certain high available total high low anti-HAV diagnostic allergic severe allergic preservative 2-phenoxyethanol severe theoretical low suboptimal common serious adverse local mild self-limited systemic serious adverse 35°-46°F 20-8°C susceptible healthy older younger chronic international active passive green several similar infectious separate early specific serologic human yellow first human early first complete serologic natural effective small double-shelled Other hepa- small circular double-stranded numerous nonhuman infectious environmental Numerous antigenic lifelong chronic chronic infected chronic hepatocellular Several well-defined antigen-antibody associ- hepatitis-associated antigenic subviral 22-nm spherical variable infec- tious complete infectious present complete detectable conventional soluble high high anti-HBs acute anti-HBs potential undefined recent anti-HBe detectable low clinical indistinguishable other acute viral incuba- average Clinical asymptomatic asymptomatic 60-150 average specific least prodromal initial insidious quadrant abdominal icteric variable character- gray hepatic common other acute complete anti-HBs acute complete fulminant serious due chronic chronic chronic many chroni- infected most early chronic asymptomatic capable responsible HBV-related chronic active more estimated higher hepatocellular 1-6 1-4 clinical epidemiologic clinical definitive early sensitive infectious chronic serologic acute anti-HBc recent detectable best serologic negative positive single chronic anti-HBc Negative anti-HBc anti-HBs due anti-HBc due natural anti-HBc anti-HBc anti-HBc possible anti-HBs Negative 1-2 immune sensitive low susceptible false positive undetectable useful protective anti-HBs positive appropriate milli-international protective supportive effective chronic successful other infective other other insect 1-2 parenteral highest serous lower other such other unlikely important transmis- sexual heterosexual homosexual Fecal-oral asymptomatic percutaneous injection-drug important other percutaneous acupunc- other sharp medical small overt needle such fresh cutaneous other infective other direct mucous such hand-to-mouth hand-to-eye infective infective mucous environmental various infec- other positive infected positive infected efficient positive perinatal positive many infected different global high positive moderate positive low positive global common global global greater most early chronic greatest most asymptomatic little acute high low low infectious present present acute 1978-2009 reportable many reportable distinct serologic different available first early injection-drug greatest acute new additional routine acute perinatal Other highest acute high-risk sexual Other occupa- healthcare-related new specific sexual uncommon general prevalent certain lifestyle highest infected frequent chronic high-risk injection-drug high 70-85 mental 10-20 35-80 illicit parenteral 60-80 active 35-80 3-10 20-80 3-6 30-60 1-8 10-80 frequent 1-2 15-30 Intermediate-Risk mental 10-25 multiple 5-20 3-10 first-time 3-5 available apparent uted several high large major infected multiple effective public private high-risk rapid begin- high-risk low initial low comprehensive pregnant perinatal high perinatal • high-risk plasma-derived 22-nm safe effective unsubstantiated trans- live other human plasma-derived infant adolescent second similar Recombinant common yeast-derived final infectious viral complete viral nant available pediatric formu- different interchangeable two-dose pediatric pediatric younger Engerix-B preservative residual single-dose other preserva- single-dose healthy more adequate age-specific three- protective higher * older immune effective clinical complete normal protective high necessary other 40-mcg special ug ug ug ug 1-10 11-15 11-19 other immunocompromised 2-dose more immunogenic specific 3-dose 4-dose antero- lateral lower least inch least inch other anterolateral valid serologic adequate anamnestic anti-HBs Available vaccine-induced intact significant clinical significant anamnestic anti-HBs significant docu- normal immune immune additional available annual younger pediatric intramuscular usual positive unknown last third fourth 6-18 unknown third least first highest last least preferable 2-month other good appropriate difficult vaccina- third least second first least third earlier necessary longer • least first positive chronologic negative HBsAg-positive unknown immunopro- additional less chronologic preterm initial gesta- tional likely full-term low negative first stable full available same pediatric equivalent individual separate positive other younger potential positive unknown first 5-compo- least high separate fourth younger fourth fifth other pertussis-containing necessary positive other pertussis- necessary same possible positive unknown routine age-appropriate adolescent vaccina- local young highest flexible older possible infec- Asian active younger pediatric Usual third first least usual less third dose minimum first minimum second third first third less minimum alternative alternative 1.0-ml postvac- anti-HBs similar 5-mcg alternative 2-dose Alternative 1.0-mL 4-6 older pediatric usual less third dose minimum first minimum second third first third less minimum necessary unvaccinated specific HBsAg-positive active long-term monogamous sexual HBsAg-positive active long-term monogamous relation- previous treat- previous recent HBsAg-positive disabled public blood-contaminated end-stage renal percutaneous current recent injection-drug HBsAg-positive disabled public blood-contaminated end-stage renal chronic percutaneous infectious -international high higher endemic international high higher endemic high disease/human drug- healthcare correctional other primary medical vacci- routine available financial available equivalent pediatric equivalent three-dose long-term first third least first second least second third least alternative 21-31 necessary recommended equivalent same single-antigen potential immune foreign-born other high higher needle-sharing positive certain immunosuppressive cost-effective high higher such injection-drug cost-effective low other higher needle-sharing HBsAg-positive immunosuppressive such routine most -chronic immunocompromised recom- such chronic other HBsAg-positive necessary HBsAg-positive least next well-child present anti-HBs present 3-dose sharp 3-dose necessary significant low such public direct second usual • 1-2 second Several older primary additional additional first second three-dose second usual 6-month 4-month recom- second valid appropriate detectable anti-HBs anti-HBs negative low detectable positive three-dose negative susceptible probable parenteral HBsAg-positive difficult negative anti-HBs possible negative true initial detectable detectable protec- true second anti-HBs sixth second expensive single positive previous further vaccina- anti-HBs negative seronegative total next same treat- high anti-HBs anti-HBs passive accidental percutaneous mucous sexual HBsAg-positive younger old primary Most high-risk cold low low valid current unavailable high chronic effective chronic effective perinatal first same different available first second third first third administra- other pediatric initial 3-dose next admin- chronologic third second fourth first different unknown positive possible important second unknown maternal reliable additional available chronic infec- HBsAg-positive off-label positive unknown younger same other older percutaneous needle next unknown available positive * anti- anti- necessary necessary unknown inadequate inadequate 1-2 immune adequate anti-HBs inadequate anti-HBs second 3-dose second Non-Occupational complete postvac- single possible separate needle-sharing positive serologic Susceptible age- appropriate Non-Occupational complete first possible severe allergic Such allergic rare allergic severe severe such upper inadvertent pregnant severe chronic pregnant eligible such suboptimal common adverse such Serious systemic adverse neurologic newborn systemic systemic rare slight large popu- lation-based frozen comprehensive comprehensive public chronic infec- occupational neonatal Clinical common cervical sexual more epidemiologic early cervical cervical genetic small double-stranded genetic cutaneous common epidemiologic cervical low-risk nononcogenic such benign low-grade cervical genital laryngeal oncogenic cervical other anogenital High-risk low-grade cervical high-grade cervical anogenital High-risk cervical cervical world- wide cervical high-risk necessary cervical vast nonmucosal/cutaneous -60 low-risk low-grade cervical anogenital low-grade cervical ·laryngeal papillomas HPV-Associated anal cervical anal/genital genital genital cervical associ- anogenital common cervical such genital non-genital oral high spon- small persistent important cervical common significant persistent genital cervical intraepithelial few infec- low-grade clear Persistent high-grade High-grade abnormali- small undetected untreated cervical asymptomatic clinical anogenital papilloma- cervical cervical cervical anal asymptomatic clinical -anogenital cervical cervical cervical anal vaginal clinical anatomic clinical high-risk positive negative type-specific equivocal atypical undetermined cervical older basic nucleic type- specific epidemiologic serologic VLP-based positive specific clinical such genital abnormal cervical other natural sexual high direct sexual sexual nonpenetrative sexual sexual prospective cumulative sexual nonsexual uncommon newborn seasonal communicable acute infec- difficult high large new sexual sexual young less epidemiologic other young sexual initia- genetic male oral common new infections/year young active common common transmitted new common young high new active common heterosexual clinic-based greater dependent anatomic Cervical new cervical cervical common cervical squamous American new cervical cervical responsible cervical cervical sible anal vaginal oral Population-based active apparent More anogenital low-risk manage- abnormal cervical cervical economic other human immuno- such significant young sexual sexual surest genital active likely future genital cervical precancerous cervical available conventional liquid-based cervical various professional American cervical sexual conventional least recom- annual biennial younger conventional liquid-based national normal consecutive cervical non-vaccine active cervical cervical major recombinant self-assemble noninfectious nononcogenic major recombinant self-assemble noninfectious nononcogenic ug ug ug antibiotic single-dose unique 3-0-desacyl-4'-monophosphoryl 3-0-desacyl-4'-monophosphoryl antibiotic available prefilled natural other dry natural vial high low high respective three-dose serologic minimal protective high clinical protective determi- serologic high type-related cervical double- placebo-controlled 18-related due 18-related genital 11-related genital double- clinical 18-related other high clinical other other more Routine young cervical other HPV-related cervical vaginal precan- genital routine recom- 3-dose complete 3-dose genital potential sexual active full less possible clinician active active three-dose intramuscular second third first third first least accelerated recom- accelerated minimum first second possible second third least third possible feasible same entire available 11-related less genital complete 3-dose same other such quadrivalent meningococcal single young separate different anatomic equivocal high-risk low-risk unlikely such younger abnormal therapeutic cervical -equivocal abnormal -positive positive specific clinical younger positive therapeutic cervical evident most other genital therapeutic severe allergic severe severe allergic moderate severe minor mild upper preg- adverse pregnant three-dose pregnant respective serious adverse common adverse clinical local clinical local such similar serious adverse similar systemic adverse equal other 15-20 freezing 35°- 20-8°C American human 626-9 quadrivalent human 630-2 human infec- human genital human global infection-associated American human young human papilloma- 157:218-26 infectious viral influ- epidemic first epidemic least 20th infectious viral least 1918-1919 inactivated protective live single-stranded nuclear other moderate other wild Most pathogenic natural stable less antigenic immunologic human subclinical epidemic isola- due sequential nuclear due larger specific interpandemic irregular major antigenic protective new pandemic new pandemic antigenic 1957-1967 major due genetic last major antigenic prior same epidemic antigenic dominant late widespread 2003-2004 minor similar predominant distant last different antigenic major 1957-1958 pandemic single high greater individual large severe fatal large Secondary tertiary 1-2 many pandemic seasonal first substantial influenza historical late pandemic influenza more younger typical seasonal older nationwide vacci- epidemic lower major high excess espe- high early respiratory subsequent 5-10 epithelial immunologic general 1-4 related nonproductive classic clinical abrupt nonproductive 101°-102°F tracheal epithelial runny substernal last more such influenza rapid several bacterial viral 0.5-1 most secondary bacterial influenza viral uncommon due Other chronic other chronic pulmonary older influenza influ- other chronic Influenza-United 1976-2007 influenza-associated influenza-associated annual older prominent influenza-associated influenza 1976-77 2006-07 annual influenza- high annual influenza-associated older prominent young influenza-related excess influ- higher older young certain under- medical more younger greater predominant high healthy high medical comparable older 24-59 less younger influenza-associated 496-1038 56-110 23-25 392-635 13-23 yrs 399-518 125-228 1-2 3-4 yrs 5-14 15-44 45-64 several highest major communi- substantial school-aged medical parental influenza-related outpa- highest major characteristic clinical amniotic certain viral demon- additional epidemiological influenza clinical helpful local individual significant influenza acute-phase less convales- human specific least fourfold diagnostic clinic antiviral laboratory avail- able chronic • airborne • large infected large upper susceptible direct indirect such influenza most peak tropical 1976-2008 documented high-risk high-risk medical two-to major more primary due epidemic esti- previous 5-year epidemic due consecutive available available intramuscular available final available pediatric 0.25-ml 0.5-ml available multiple single multi-dose preservative-free influenza influenza available annual -intramuscular -trivalent new influenza sanofi older much regular clinical higher higher influenza prefer- high other older influenza same cold-adapted final residual single-dose other healthy nonpregnant nasopharyn- attenuated cold-adapted temperature-sensitive nasopharyngeal cold-adapted temperature-sensitive practical influ- vaccine-induced antigenic effective healthy younger similar effective effective healthy effective effective effective effective clinical effective elderly effective effective unvac- likely 1982-1983 healthy healthy double-blind placebo- healthy culture-confirmed influenza culture-confirmed Other concomitant antibiotic effective old febrile antibiotic double-blind placebo-controlled healthy several influenza outbreak 1997-98 fewer severe fewer febrile upper fewer due fewer due fewer antibiotic greater greater available annual older higher influenza-related older earlier influenza high- 2010-2011 second seasonal seasonal prior intra- Other such intradermal subcutaneous topical 6-35 previous 2010-2011 annual older higher older older chronic renal hepatic hematologic metabolic human pregnant long-term older chronic cardiovascular renal hepatic hematologic metabolic immu- other American obese greater younger older particular younger medical higher severe pregnant influ- long-term other obese greater younger older particular younger medical higher pregnant serious medical immunologic second third nonpregnant comparable higher nonpregnant comparable nonpregnant high-risk medical pregnant nonpregnant high-risk medical recom- pregnant pregnant Many protective low protective many HIV-infected many HIV-infected transient clinical serious influ- protective many other close high-risk long-term facili- high-risk likely elderly annual other outpatient high-risk healthy younger immunosuppressed severe healthy eligible available late 2010-2011 second seasonal seasonal prior 2-8 previous 5-8 previous previous high eligible healthy pregnant Other such Other live same same least possible Other live same same severe allergic severe allergic previous previous chronic medical long-term inactivated younger older chronic medical recent other chronic cardiovascular such renal such long-term other wild-type anaphylactic other previous younger severe other live-virus immunosuppres- sive residual other Guillian previous influenza moderate severe clinical nasopharyngeal deferral administra- antiviral influenza antiviral replica- antiviral influenza antiviral adminis- common adverse common previous viral last 1-2 Recent systemic common rare immediate such allergic likely residual current small immediate severe acute respira- appropriate occupational other allergic influenza similar medical influenza potential intradermal indicate local delayed-type subsequent other small difficult rare such annual popu- less true adverse lower severe older medical general low greater greater prudent previous most high severe vaccina- significant other systemic reactive 12-59 serious adverse common adverse nose significant clinical older healthy higher serious adverse small such rare adverse available such immunosuppressed cardiac additional available high insu- lated coolant 35°-46°F visible present tempera- possible total first upright second other fewer high-risk effective high-risk automatic adverse physician influenza iden- other residential long-term facili- acute high-risk hospital outpatient high-risk high-risk necessary unvaccinated other prior appropriate organiza- high-risk oseltamivir many resistant recom- rimantadine antiviral re-established new active dry uncomplicated older symptomatic oral uncomplicated older symptomatic more older influenza older 2007-08 significant osel- 2007-08 resistant 2008-09 positive recent local likely resistant antiviral available Antiviral adjunct influenza-related antiviral current state- general high susceptible inacti- vated high-risk medical antiviral high-risk protective Other elective uncomplicated new necessary influenza-related economic rapid preven- unvaccinated high-risk new influenza-related economic rapid preventive weekly sporadic regional less widespread available special influenza live cold-adapted influenza Influenza-associated seasonal influenza 1976-2007 Hospital-based pneumococcal preven- live 361:1260-7 asthmatic 106:931-3 interpandemic younger prospective healthy placebo-controlled double immuniza- acute viral infectious early Persian contagious viral universal fatal lifelong human live available immune common fatal 100-200 single-stranded important responsible viral responsible important antigenic impor- acidic short less systemic primary regional primary subsequent viral regional distal second initial other nasopharynx 3-4 regional 2-3 5-7 higher • 1-7 charac- high mucous pathognomonic 1-2 1-2 blue-white bright red buccal 2-4 • 5-6 maculopapular upper next gradu- maculopapular discrete upper 3-4 involved same Other more common younger older viral bacterial common 1985-1992 stiff pleocy- approxi- residual neurologic many 5-19 other higher young common acute measles-related rare degen- erative central nervous due insidious progressive early higher spontaneous low-birthweight definable malfor- subse- wild-type Subsequent pleural maculopapular petechial urticarial vesicular local severe immune young residual mild discrete short mucous certain typical several high younger severe particu- bacterial case-fatalit high important molecular epidemiologic surveil- geographic viral clinical urine nasopharyngeal public viral same likely more detailed viral isola- available //www.cdc.gov/ enzyme-linked available diagnostic susceptible wild-type many negative negative positive previous single diagnostic positive other positive first false negative negative first detectable least available indirect possible second same same specific second inter- indigenous other late winter-spring human asymptomatic large communicable greater secondary susceptible 1950-2009 actual More highest 2–3-year epidemic indigenous lowest annual school-aged younger younger first school-aged recom- second 1989-1991 dramatic school-aged largest younger first younger 5–19- highest lowest non-Hispanic higher non-Hispanic measles-associated death-to-case younger fatal largest annual important low low many large preschool-aged early experi- preschool-aged few second black likely white younger high other many young due wild smaller higher susceptible younger many other due preschool-aged vacci- 2-year-old low annual fewer fewer low annual other other aggressive low indigenous importation-related older high many prior second recom- school-aged school-aged uncommon largest annual other several younger most personal religious unknown greater importation-associated school-aged eligible Many home-schooled subject clinical clinical www.cdc.gov/vaccines/pubs/surv-manual/default.htm first unique atypical wild-type original high live fewer original measles- available live available individual available freeze-dried sterile preservative-free small human noncom- Most vaccine municable similar primary other first first first serologic vaccine-induced lower natural serologic epidemiologic vaccine-induced long-term Most vaccinated anamnestic available secondary successful minor least least other adoles- first first measles-containing first minimum valid older second first catch-up least first first additional other acceptable first second possible less first first primary 12-15 least valid Self-reported parental other acceptable permanent medical older first first older separate equivalent medical least vaccina- least measles- mumps- other acceptable pregnant medical acceptable special other post-high educational medical international other post-high educational potential high-risk large susceptible universi- technical other post-high other acceptable medical other acceptable first prior other measles-containing first second least previous medical higher general medical medical nonmedical full susceptible medical private public possible elderly low live least live second least first unvaccinated labo- appropriate unvaccinated medical cost-effective susceptible necessary other acceptable timely serologic endemic epidemic many other certain unvaccinated least first last unknown unknown necessary unknown unknown permanent temporary susceptible younger highest live severe allergic vacci- severe anaphylactic serious measles- anaphylactic measles- other such serious egg-allergic low skin-testing predictive allergic vaccina- egg-allergic prior routine special chick egg-allergic other pregnant pregnant due large virus subsequent least immunocompromised immu- susceptible immunocompromised general large daily least high-dose low-dose short-course less alternate-day topical intra-articular high systemic component least severe infec- severe unusual adverse variable asymptomatic symptomatic other measles-containing theoretical other clinical such asymptomatic severe immuno- other measles-containing severe severe ill potential such mild upper antibiotic other Age-specific severe HIV-infected uL ul ul antibody-containing immune whole red intravenous immune such immune intravenous thrombocytopenic low significant direct vaccine-induced natural greater potential justified greater thrombocy- subsequent previous previous such personal vaccina- personal such personal same least • least vaccina- other measles-containing same admin- measles-containing same measles-containing least theoretical allergic subsequent susceptible adverse rare rare common adverse susceptible higher Most asymptomatic higher oral 5-12 additional separate same second same separate same susceptible temporal clinical greater MMR-associated higher immune other rubella-containing other other susceptible Allergic compo- Most minor anaphylactic rare uncommon possible second independent nongovernmental American available current frozen same inadver- tent American Red American 43:451-63 wild-type global fatal rubella-vaccine strate- congenital vari- health-care recommenda- January-July 58:1321-6 undervaccinated 125:747- second severe meningococcal first definitive spinal bacterial focal sub-Saharan bacterial menin- focal such sub-Saharan meningococcal first major meningococcal aerobic gram- negative several such cytoplasmic several other gram-negative least invasive geographic other necessary complement-mediated main serologic distinct asymptomatic groupable invasive relative other such major certain outer Molecular pulsed-field elec- useful epidemiologic secre- small colonized many bacteremic blood-brain cerebro- spinal Clinical meningococcal common invasive meningococcal hematogenous similar other sudden other such mental 1992-1996 common hematogenous -stiff invasive meningococcal abrupt petechial purpuric acute adrenal multiorgan common meningococcal -petechial invasive meningococcal appropriate antibiotic many such neurologic meningococcal common functional anatomic meningococcal genetic such terminal genetic upper demographic socioeconomic active meningococcal upper active passive low higher low likely such nightclub invasive meningococcal least fatal sterile bacterial low particu- antibiotic cerebrospinal gram-negative meningococcal cerebrospinal rapid specific false-negative common unreliable meningococcal clinical meningococcal similar other bacterial empiric broad-spectrum third- appropriate empiric antibiotic effective Few penicillin-resistant peni- endemic epidemic natural many asymptomatic most pathogenic groupable direct highest early meningococcal secondary Most secondary secondary 2-4 general gococcal meningococcal major menin- gococcal responsible younger available meningo- coccal older vaccine-preventable meningococcal historic routine recom- annual meningococcal 5-14 15-24 25-39 40-64 meningococcal meningococcal meningococcal meningococcal mean mean vaccina- 1.5-4.6 underlying meningococcal sporadic Most additional menin- gococcal recent meningococcal endemic meningococcal several higher subcutaneous 10-dose vial meningococcal current bacterial subcutaneous available single-dose 10-dose available single-dose sterile 10-dose sterile clear available meningococcal intramuscular capsular isotonic meningococcal intramuscular single-dose lyophilized meningococcal ug capsular polysac- injec- intramuscular similar other polysac- pneumococcal effective younger typical independent age-dependent poor younger little low-affinity poor protective 7-10 younger first single healthy detectable vaccine-induced likely school-aged least younger more younger older single similar single meningococcal similar least fourfold following non-inferior single least serologic available significant few suffi- highest meningococcal single meningococcal sufficient persistent 2-dose primary recom- available 1-time first routine routine meningococcal higher first adoles- first one-time routine meningococcal healthy healthy older first meningococcal -military hyperendemic epidemic meningococcal military hyperendemic epidemic sub-Saharan dry annual geographic high-risk first meningococcal first older meningococcal previous persistent functional anatomic 2-dose other such international least complement functional anatomic second earliest valid preferable possible other such international least same other indi- separate separate probable primary meningococcal vaccine-preventable probable primary meningococcal less primary more population-based age-specific meningococcal applicable other vaccine-preventable menin- gococcal -primary Population-based severe anaphylactic severe routine minor vacci- adverse available consid- frequent local such last 100°-103°F such Fewer severe severe adverse similar frequent local 100°-103°F such recipi- systemic severe 1-2 • other imme- rare necessary interna- tional minimum incomplete meningococcal most healthcare invasive meningococcal local sporadic meningococcal antimicrobial oral mouth-to-mouth antimicrobial direct sporadic meningococcal 500-800 greater total meningococcal higher general secondary highest antimicrobial possible less chemoprophylaxis limited nasopharyngeal helpful preventive effective acceptable antimicrobial antimicrobial other other eradicate other chemoprophylactic meningococcal revaccina- meningo- coccal meningococcal in- gococcal young 286:694-9 meningococcal meningococcal laboratory-acquired meningococcal 43:4811-4 acute viral filterable frequent military common aseptic common reported viral • military same cross-react single-stranded various human cerebrospinal chloro- ultraviolet regional such characteristic aseptic regional 12-25 nonspecific low-grade 14-18 low-grade asymptomatic common infected unilateral bilateral single salivary many asymptomatic additional nonspecific clinical post- nervous aseptic cerebrospinal common higher absent many such rare less testicular common compli- postpubertal many postpubertal bilateral abrupt last testicular rare ovarian post- infrequent reversible single many temporal few unilateral vestibular sudden compatible symptomatic rare Other less common arth- clinical particular clinical preferred salivary viral -positive -significant simplest available sensitive other available detectable first few possible symptom acute-phase negative sensitive clinical clinical available late human asymp- tomatic nonclassical active airborne direct infected similar infectious active saliva 1968-2009 reportable Mumps-United 1980-2009 relative highest resur- older routine high single highest usual fewer largest old laboratory-confirmed outbreak-related less largest mumps-containing 2009-2010 close large less intense plausible few other clinical clinical epidemiologic www.cdc.gov/vaccines/pubs/surv-manual/default.htm inactivated short- lasting mid- live least dose available individual available freeze-dried sterile preservative-free small human noncom- single measurable similar single effective older high school- high international post-high educational vaccine-induced greater lifelong vaccine mumps-containing recom- high mumps-containing first Mumps-containing least second school-age high international post-high educational second catch-up vaccina- first valid Self-reported parental adequate clini- other acceptable permanent medical older first first older separate least live first acceptable “ equivocal sero- susceptible • unvaccinated appropriate unvaccinated immune immune effective severe allergic severe anaphylactic serious measles- mumps- anaphylactic measles- other such serious such egg-allergic low skin-testing predictive allergic egg-allergic prior routine special chick fibroblast allergic theoretic fetal malig- immune immunosuppressive low-dose less alternate-day topical immunosuppressive additional human immunodefi- severe mild upper antibiotic other antibody-containing immune whole red intravenous immune sero- least antibody-containing safe Most adverse such joint attributable compo- adverse large-scale few rare rare vaccine inadequate relation- aseptic sensorineural mild adverse frozen same inadvertent refrig- 2009-January strate- congenital unvaccinated available effective 47:1458-67 preventable infectious first contagious common major more widespread more major small aerobic gram-negative fastidious special multiple antigenic active filamentous responsible clinical permanent Fastidious gram-negative active filamentous toxin-mediated epithelial pulmonary recent present alveolar toxin-mediated epithelial 7-10 clinical 7-10 4-21 similar upper first insidious runny low-grade occasional similar common severe 1-2 second paroxysmal minimal 1-6 numerous rapid due thick long characteristic high-pitched cyanotic young ill ill asymptomatic classic first same gradu- younger gradual paroxysmal subsequent many young asymptomatic present classic common older other susceptible unimmunized incom- immunized Older first multiple common pertussis-related secondary bacterial highest pertussis- younger such encephal- common Other serious compli- severe subdural rectal 6-11 10-19 y 1-4 5-9 younger 2004-2008 such urinary characteristic posttussive direct specific fastidious difficult posterior highest first paroxysmal positive late clinical likely positive more cough several medical atten- late useful many poor high false-positive nasopharyngeal negative prior antibiotic viable positive essential useful rapid monoclonal low useful likely negative available positive recent remote recent such serologic white present classical greater More laboratory available //www.cdc.gov/vaccines/pubs/surv-manual/default.pdf medical supportive communi- antibiotic effective such azithro- trimethoprim-sulfamethoxazole close younger four-dose minimal 4-6 second fifth postex- unknown important most respiratory airborne infected distinct seasonal communicable secondary susceptible infectious cough ni 1940-2009 Secular common 6-year whole-cell Year 1980-2009 annual fewer early largest clear 1990-2008 11-18 highest average annual younger recent older annual older unpublished demographic informa- many useful epidemiologic highest greatest severe recent additional www.cdc.gov/vaccines/pubs/surv-manual/default.htm formalin-inactivated clinical subsequent observational primary whole-cell effective serious little last Local such other mild systemic common more purified adverse available many other 5-10 Local adverse common inactivated Several acellular different different available available sanofi equal available 2-phenoxyethanol single-dose available pediatric similar pediatric same single-dose 59-90 several effective acellular signifi- effective whole-cell local systemic serious such high hypotonic hypo- acellular various pediatric single similar new similar clinical similar 4-to 8-week fourth 6-12 third other 15-18 fourth recom- certain fourth fourth least least third unlikely additional fourth 15-18 unlikely 15-18 primary fourth necessary fourth primary fourth 17-20 whole- same possible same possible limited available available earlier acellular eligible different necessary primary single single acellular last single additional single older younger single other older single last tetanus- diphtheria-toxoid routine diph- single 19-64 older pregnant single feasible next fewer last pregnant single pregnant certain such pregnant certain such second third coincidental spontaneous common first catch-up high younger other vulnerable 1-37 direct single feasible direct younger last direct single feasible direct younger last dose same other permanent single least such tetanus- first formula- least dose least dose off-label first protective least high separate other pertussis-containing necessary positive fourth younger * off-label fourth fifth other pertussis- necessary same possible positive least fourth third least fifth older Other certain neurologic neurologic uncontrolled progressive neurologic neurologic neurologic other neurologic stable neurologic idiopathic cerebral developmental full multiple smaller altered significant likely full smaller standard additional pediatric typical clinical culture-confirmed eligible additional eligible typical clinical such other other certain severe allergic compo- prior due identifiable prior identifiable severe vaccina- such upper severe acute condi- infrequent adverse vaccina- subsequent pediatric higher due identifiable shock-like inconsolable severe higher other identifiable shock-like hypotonic inconsolable longer • precautionary adverse additional severe encephalopathy due identifiable pertussis-containing allergic prior identifiable pertussis-containing previous toxoid-containing progressive such uncontrolled severe local prior toxoid- least last Td-containing severe severe previous toxoid-containing neurologic severe local prior severe certain such higher shock-like persistent subsequent adverse stable such controlled cerebral precau- local such frequent fourth systemic such low-grade higher self-limited symptomatic severe such higher febrile hypotonic hyporesponsive common fewer comprehensive higher severe adverse common common adverse full substantial local fourth fourth fourth other systemic supplemental entire entire upper certain acellular substantial local condi- self-limited entire fourth extensive fourth fifth fourth fifth common adverse local such higher nonspecific such gastrointestinal same acellular serious higher • same acellular frozen adminis- tered Pertussis-Containing 2°-8°C frozen American young antimicrobial acellular acellular 2001-2003 acellular bacterial infec- pneumococcal other pneumococcal bacterial Pneumococcal other More effective pneumococcal many antibiotic late pneumococcal first pneumococcal first conjugate pneumococcal Gram-positive important protective lancet-shaped gram- positive facultative anaerobic short pathogenic experimental primary antigenic type-specific Type-specific protective pneu- pneumococcal other additional serious few pneumococcal common invasive geographic common cerebrospinal younger older common healthy asymptomatic upper respira- military many natural major clinical pneumococcal pulmo- nary community- hospital-acquired higher elderly common clinical pneumococcal invasive pneumococcal short abrupt single Other common pleuritic rapid poor rapid many pneumococcal community-acquired hospital- common bacterial much higher elderly pneumococcal pleural endobronchial higher elderly young pneumococcal overall high elderly fulminant clinical bacterial pneumococcal pneumococcal pneu- clinical similar other purulent bacte- rial nuchal cranial pneumo- coccal high elderly common pneumococcal elderly common implant invasive pneumococcal immune functional anatomic chronic pulmonary renal immune functional anatomic ary renal common invasive clinical pneumococcal younger invasive invasive pneumococcal younger invasive bacterial younger routine pneumococcal younger highest pneumococcal common clinical bacterial common middle least Middle ear frequent pneumococcal routine pneumococcal pneumococcal younger significant invasive pneumococcal invasive pneumococcal invasive younger anatomic sickle implant functional anatomic human high higher same certain racial ethnic particular certain American Indian invasive pneu- mococcal 2–3-fold younger cochlear pneumococcal definitive other sterile available capsular lancet-shaped suggestive difficult normal pneumococcal white fewer epithelial gram-positive capsular capsular rapid clinical spinal pneumococcal positive large rapid pneumococcal other available sufficient invasive pneumococcal other common invasive pneu- mococcal resistant antibiotic available Pneumococcal human pneu- asymptomatic insect early | direct person-to-person upper pneumococcal responsible such upper such pneumococcal high common early prevalent pneumococcal unknown respiratory pneumococcal population-based More invasive pneumococcal More indica- pneumococcal nonbacteremic noninvasive overall invasive pneumococcal other sterile approxi- highest invasive pneumococcal young younger invasive invasive pneumococcal lowest older overall invasive pneumococcal < 2-4 5-17 18-34 35-49 50-64 younger pneumococcal major invasive young overall invasive younger 1998-1999 first pneumo- coccal invasive particular 14-valent 23-valent 7-valent 13-valent purified pneumococcal first pneumococcal capsular different pneumococcal 23-valent Pneumococcal 14-valent poly- pneumococcal bacteremic pneumococcal several capsular additional bacteremic available preserva- available single-dose 5-dose bacteremic pneumococcal additional invasive pneumococcal younger pneumococcal capsular nontoxic 13-valent pneumococcal serotype total same invasive pneumococcal younger attributable serotype healthy younger poor pneumococcal effective invasive effective pneumococcal least healthy more certain underlying various clinical effective invasive effective pneumococcal significant underlying effective normal such high severe pneumococcal pneumococcal significant vaccine-type non-vaccine-type young high-risk medical effective invasive effective large clinical invasive fewer underwent fewer unvac- naso- pharyngeal pneumococcal comparable protective invasive 7-11 12-23 24-71 pneumococcal age- appropriate comparable 3-dose lower 24-71 adminis- older older normal chronic cardiovascular pulmonary cerebrospinal cochlear older -chronic functional pneumococcal splenic surgical chronic renal nephrotic such organ immunosup- high-dose longer older asymptomatic symptomatic special social pneumococcal such certain new pneumococcal older new invasive pneumococcal Available indica- elective cochlear consid- feasible possible 2-week other immunosuppressive possible complete uncertain unknown pneumococcal same different most single Pneumococcal early older fewer fourth same other routine separate younger minimum older least :1-19 7-11 12-23 detailed previous available dose 24-59 healthy 24-71 medical older full current least least healthy single certain chronic medical least chronic cerebro- spinal other functional anatomic single age-appropriate complete medical single least recent final single invasive pneumo- coccal anatomic such cochlear cerebrospinal healthy medical fewer least medical incomplete least elective splenec- implant vaccina- least Pneumococcal invasive certain higher available pneumococcal substantial Pneumococcal highest serious pneumococcal multiple pneumococcal revaccina- immunocompetent 23-valent older highest serious pneumococcal likely rapid pneumococcal high-risk previous highest severe pneumococcal Pneumococcal -functional anatomic renal -nephrotic highest older functional anatomic multiple chronic renal nephrotic other organ immunosuppressive long-term older second younger first primary severe pneumococcal severe allergic Such allergic rare severe such upper pregnant adverse inadver- high pneumococcal pneumococcal possible Adverse rare common adverse pneumococcal local less second first such common fewer severe systemic adverse rare clinical immunologic dete- such local severe common fourth first clinical higher primary such rare adverse clinical hyporesponsive anaphylactic/anaphylactoid angioneurotic injection-site injection-site injection-site unknown insulated coolant contami- least pneumococcal older population-based random-digit-dialed older older pneumococcal lower chronic older older chronic high-risk other long-term severe pneumococcal 3-5 few severe pneumococcal few pneumococcal high pneumococcal subse- high significant compli- pneumococcal pneumococcal pneumococcal 13-valent pneumococcal 23-valent pneumococcal invasive pneumococcal 23-valent pneumococcal pneumococcal young 13-valent pneumococcal revac- pneumococcal 281:243-8 invasive pneumococcal 201:32-41 invasive pneumococcal pneumo- coccal 46:1664-72 pneumococcal recommenda- pneumococcal pneumococcal spinal spinal paralytic next ible recognizable first early next severe average older paralytic effective last wild-virus global next transient gastrointestinal stable small ether-insensitive • minimal signifi- other ultraviolet primary multi- gastrointestinal several local central nervous anterior destruc- typical local central nervous variable clinical asymp- tomatic able non-CNS minor nonspecific clinical laboratory central nervous clinical abortive complete less poliovirus upper gastrointes- tinal abdominal consti- indistinguishable other viral aseptic several similar last complete normal biphasic initial minor 1- major superficial deep asymmetrical most present permanent common paralytic most cranial spinal paralytic cere- brospinal diagnostic flaccid genomic deter- wild high fourfold white wild inapparent asymptomatic immune fecal-oral important oral-oral seasonal tropical infectious susceptible greater susceptible infectious possible early maternal high continual paralytic immediate frequent primary natural susceptible para- lytic early oral paralytic last paralytic endemic wild several paralytic last imported recent direct vaccine-associated paralytic live oral Last Indigenous 1980-2009 last unvaccinated second vaccine-derived several asymptomatic unvaccinated least genetic early other first available sanofi monkey 2-phenoxyethanol formaldehyde single-dose subcutaneous intramuscular injec- monkey single intestinal viral first fecal effective least • effective protective least immune paralytic local wild many complete effective Oral effective single more other live-virus oral lifelong excellent intestinal wild lower low fourth fourth similar other exclusive paralytic 1996-1999 sequential paralytic sequential vaccine-associated paralytic sequential humoral inactivated third fourth available sequential complete complete complete paralytic available indigenous primary other first early second third 6-18 first final previous minimum next-to-last final 15-18 additional age-appropriate IPV-containing 5-dose acceptable 4-6 least optimum available 4-6 complete younger lower first imminent polio-endemic available routine 4-6 complete minimum older necessary polio-endemic first fifth fourth component older older necessary immune small endemic epidemic eastern close wild specific current wild previous available unvaccinated prior third second minimum second third possible 1-2 6-12 first second minimum second third available available least available single primary more increased further supplementary supplemental recom- complete necessary additional endemic complete full last necessary severe allergic compo- prior further allergic anaphy- lactic such severe successful immuniza- upper local prior current antimicrobial contraindica- same individual local serious local serious adverse allergic Vaccine-Associated available paralytic 5-10 exclusive Most healthy Vaccine-Associated paralytic rare adverse live oral live paralytic identical permanent likely immuno- higher certain available iden- paralytic older Vaccine-Associated paralytic healthy average healthy average vaccine immunologic immuno- abnormal other overall paralytic other able revertant similar last clear preliminary clinical paralytic 404-639- appropriate local appropriate viral Last • free Last single paralytic immediate vaccine-associated unvaccinated epidemic older uncertain widespread many paralytic more fewer last indigenous wild acute flaccid supplemental such national last wild-virus-associated indigenous additional intensive international free indigenous detailed national global substantial paralytic fewer endemic last international Other bilateral multilateral Current global available paralytic new new syndrome permanent residual paralytic poliomy- infectious more post- Post-Polio 63108-2915 314-534-0475 vaccine-associated paralytic wild updated global wild routine early bacterial viral parasitic fewer intestinal common severe young responsible diarrhea Second- common severe Responsible diarrheal double-stranded important younger more define stable viable stable viable envi- many animal anti- distinct human villous small small systemic uncommon immu- intestinal decreased intestinal isotonic small uncommon important Cell-mediated important first permanent single natural infec- severe greater severe first tomatic mild low-grade less most severe asymptomatic severe clinical first severe asymptomatic self-limited severe greater clinical nonspecific similar other severe prolonged young severe metabolic solid severe multiple organ available Several commercial available common human simple inexpensive sensitive Other such nucleic present routine diagnostic fecal geographic present gastrointestinal many nonhuman rare clinical immuno- true high fecal-oral such other environmental other such respiratory annual epidemic seasonal unknown tropical seasonal communicable universal large common notifiable special younger infec- similar improved sufficient younger low passive maternal clinical highest asymptomatic responsible direct responsible younger common severe higher severe hospitaliza- younger seasonal responsible more physician more hospi- due nosocomial immuno- deficiency-related nosocomial severe live young new live devel- predominant rhesus-based 20-fold first smaller 5-fold age-dependent relative first live oral human 2-mL infectious sucrose monobasic fetal present human early live live oral live least median infective sterile various dose clinical more physician rotavirus-related severe large first fewer clinical more two-dose severe fewer general similar other • oral previous routine admin- oral previous same other maximum maximum FDA-approved different other clini- -minimum first off-label maximum first minimum maximum older maximum labeled maximum maximum 8- necessary maximum preferable 8-month necessary few more partial least least same possible available available same possible available available prior full 2- 3-dose least diar- multiple initial partial full 2- 3-dose severe allergic anaphylactic oral severe free allergic prior oral adverse general vacci- vaccina- adverse severe other acute congenital hematopoietic solid severe fatal available administra- due severe present less HIV-exposed preferable wild-type other acute other mild acute first chronic available theoretic available -ACIP higher other rota- available previous available immune antibody-containing immunologic oral full adverse -chronological least stable neonatal intensive Available first clinical small preterm evalu- preterm adverse same full-term chronological stable neonatal intensive lower maternal adverse eligible stable theoretic theoretic same eligible usual small immune indirect wild-type small pregnant same pregnant low such good • pregnant low clinical large able vaccine clinical more dose dose intus- higher Other other adverse clinical similar unvaccinated serious adverse attributable adverse possible 350- 2-8°C possible alcohol-based pregnant reportable medical sensitive specific national national rotavirus-specific rotavirus-compatible surveil- local case-control retrospective routine national new unusual vaccina- American severe 1993-2003 oral intro- human first European 370:1757-63 little red little “ third separate medical common “ German viral viral distinct clinical German widespread Australian congenital maternal early first such eastern western single other unstable lipid low antigenic low replica- regional mitotic regional 5-7 subclinical first rare older lymphadenopathy upper maculopapular • 12-23 low-grade 14-17 second pruritic hot last several posterior cervical many integral Other soft diagnostic common rare rare same last chronic rare rare secondary low thrombocytopenic common cerebral intrarenal last Additional late progressive main vaccina- 1964-1965 surgical/spontaneous emotional severe early gesta- congenital fetal spontaneous many first fetal rare overall third greater uncomplicated fetal organ common sole congenital fourth such ventricular pulmonic possible mental other hepa- spleen progressive panenceph- older higher low high many subclinical reliable acute positive viral rubella-specific significant acute- clinical serologic urine cerebrospinal diagnostic viral intensive many labora- routine valuable epidemio- www.cdc.gov/rubella/lab/ common serologi- significant acute- possible False-positive positive infectious positive available available preferred Enzyme-linked sensi- available easy diagnostic animal true 5-7 airborne trans- insect subclinical asymptomatic highest contagious contagious more large susceptible 1966-2009 notifiable largest annual fewer moderate due low annual independent avail- able careful longer 1980-2009 younger older Hispanic young largest annual due susceptible young Most reported foreign-born unvaccinated many many Latin American clinical clinical congenital www.cdc.gov/vaccines/ higher joint vacci- human other live aborted human least dose communicable available measles-mumps-rubella individual available freeze-dried sterile preservative-free small human safe immunogenic older serologic single More vaccinated clinical least Follow-up long-term lifelong similar single-antigen Several low detectable unknown uncommon clinical fetal vaccine-induced pregnant least rubella-containing combi- older least first first rubella- least older Susceptible nonpregnant first second second avail- able first second second dose long- available combined second first second first minimum older least younger medical least least measles- mumps- other acceptable high second susceptible pregnant valid Self-reported parental other acceptable permanent medical older first first older separate least other live first equivocal serologic rubella-susceptible acceptable routine presumptive unvaccinated congenital acceptable pregnant positive appropriate pregnant acceptable pregnant immune least unvac- important pregnant detectable unreliable many many reliable previous reliable stan- negative Such serologic medical cost-effective susceptible timely prior necessary other acceptable immune effective allergic dose severe pregnant pregnant fetal malig- immune immunosuppressive low-dose less alternate-day topical immunosuppressive asymptomatic symptomatic severe mild upper antibiotic other antibody-containing immune whole red intravenous least antibody-containing necessary Previous human immune contra- anti-Rho 6-8 personal vaccina- personal such personal serious safe Most adverse such attributable common lymphadenopathy adverse common rare susceptible arthritis-like persistent Population-based such joint susceptible susceptible susceptible postpubertal acute arthritis-like periph- eral neuritic such acute 1-3 other chronic seronegative seronegative unimmunized neuropathy adverse pregnant pregnant likely pregnant next pregnant other theoretical pregnant vaccina- routine pregnant likely next pregnant pregnant theoretical 1971-1989 pregnant such live subclinical susceptible susceptible vaccine-induced maximum theoretical low routine small theo- retical pregnant frozen same inadvertent indigenous main- susceptible adoles- young routine premarital possible at-risk special supplemental susceptible immune important susceptible American Red American rubella-vaccine strate- congenital pregnant congenital rubella-containing vari- congenital preventable fatal convulsive skeletal 5th clinical fatal human same specific protective passive early gram-positive sensitive resistant usual other • gram-positive spore- human ng/kg intes- Manure-treated large agricultural significant human tetani tetano- clinical minimum human 70-kg central nervous unopposed low several central nervous peripheral spinal sympathetic nervous typical clinical unopposed autonomic nervous 3-21 clinical local common rare common spasms 3-4 complete general further central nervous longer higher neonatal clinical different same anatomic many gener- fatal rare ear present middle cranial facial common first trismus abdominal Other episodic rapid last several 3-4 newborn protective 2000-2003 generalized newborn protective passive immune unhealed umbilical unsterile common more annual 2000-2003 rare vocal sustained nervous abnormal common Secondary hospital-acquired elderly common autopsied recent likely fatal older unvaccinated obvious direct clinical demon- foreign tetanic supportive adequate critical single immune available extreme minor other practical useful proper important active primary older last dose last dose clean minor uncertain early temporary protective encoun- populated hot organic intestinal • major minor recent higher likely elective deep dental contagious contagious vaccine-preventable infectious contagious 1947-2009 early late late notifiable 500-600 50-100 ~0.05 recent all-time older younger younger last younger younger older younger young injection-drug late 1980-2003 5-14 15-24 25-39 primary 1991-1995 1991-1995 high Other recent available available frequent common Other barbed insect available other intravenous other chronic least primary injection-drug last fewer unknown 7-8 5-12.5 prior pediatric older 10-64 formaldehyde-treated available equal higher nima available single-antigen pediatric acellular available Pediatric similar younger pediatric older pediatric single-antigen available primary older younger greater protective protective complete clinical last last rare last minimal protective small minimal protective other clean last fewer acellular usual second third fourth third less Primary 15-18 valid younger old first older first younger older primary first third second primary fourth fourth fourth fourth optimal last least last dose next frequent local adverse 11-12 older primary prior diphtheria- unvaccinated older primary first least third dose second first single unvac- recommended small active severe allergic useful appropriate discon- severe routine minor toxoid-containing other clean dose additional systemic common local systemic rare adverse common self-limited palpable several other systemic common 5- Exaggerated local diphtheria- tetanus- extensive painful frequent severe high severe local prior such generalized few peripheral neuropathy available brachial rare ven tetanus-toxoid-containing 20-8°C other preventive acellular young acellular acellular “ high-risk ” WHO-recommended neonatal infectious Primary chick- infectious vesicular vesicular chick- first other first latent short regional primary other such sensory secondary viral regional antibody-containing • 14-16 10-21 1-2 several present several pruritic highest centripetal mucous respi- superficial clear erythematous several present several macular same successive clinical healthy severe higher gastrointestinal severe progressive high extensive vesicular high prolonged primary healthy second common other viral natural wild clinical detectable younger latent under- young younger immunocompromised skin central nervous pulmonary hepatic vesicular unilater- fifth few systemic e respi- viral bacterial nervous syndrome 2-3 self-limited bacterial infec- common outpatient medical serious hospital- viral bacterial Secondary bacterial common younger nervous aseptic common good infrequent cerebral common unusual vari- unknown dramatic other y aseptic thrombo- older • younger 2-3 healthy Most immunocompetent ler- se 1990-1994 nav healthy older younger vari- 1-4 5-9 10-14 15-19 er- 1923-90 high organ fulminant pneu- maternal overwhelming high severe fetal passive maternal prior due passive maternal available last longer other severe maternal low first maternal first newborn low muscular cortical first congenital primary maternal low less Rare congenital maternal virologic maternal useful necessary atypical adverse immunized issemi- clinical available standard frequent sensi- several frequent vesicular wild-type severe unusual specific antiviral rapid clinical Real-time avail- able sensitive available available several real-time unavailable direct sensitive meticulous ng prefer- fresh fluid-filled Other such nasopharyngeal bronchial desirable skin positive such likely viral viral positive viral negative reliable valid distinc- tive subclinical unusual necessary logic useful available latex enzyme-linked available sensitive robust sensitive specific available available sensitive simple rapid sensitive commercial false-positive useful lower Commercial sensitive vaccine-induced potential false- negative routine significant standard commercial available false- positive common high reliable 404-639-0066 404-639-3667 e-mail occur tropical more rural early 1-2 4-5 human insect common tract secre- airborne direct acute distinct seasonal highest early highest lowest tropical seasonal first contagious entire new logic nificant false contagious contagious more Secondary susceptible high Secular 1990-1994 1-4 6-9 10-14 16-19 notifiable younger highest age-specific earlier older 1995-2004 active varicella-related active surveil- 1-4 icela 1-4 5-9 10-14 15-19 19–35-month-old high one-dose high many elementary highest younger high current one-dose vaccina- second notifiable least cellular important • combi- Varicella-Containing older older viral early healthy general older sequential embryonic embryonic small residual sterile live attenuated identical equal higher small human potas- other sterile older same higher small residual sterile effective effective severe detectable More least Japanese infec- moderate severe healthy older second least second first long-lasting fewer fewer many maculopapular Most long-lasting unvaccinated consistent most vaccina- recent younger several higher less live viral vari- 2.5-fold increased second 1058-61 antigenic clinical healthy single similar separate ectable unst primary clinical more prior single fewer highest older severe postherpetic fewer older severe postherpetic feier through15 regard- prior 12-15 4-6 younger second same second second least first minimum younger second least first second second older older varicella-containing subcutaneous safe effective healthy same separate separate same least separate separate other other althy milar clinician-diagnosed verified typical immune such clinical older older least first second first older least desirable higher highest likely susceptible cost-effective necessary uncertain likely cost-effective necessary seropositive available commercial sensitive full available clinical infectious other constitutional atypical susceptible low susceptible potential vaccine-associated medical high serious such eceive older eligible first second younger minimum second least first second older first first second first older separate older single older prior chronic medical single older prior chronic medical 23-valent pneumococcal same clinical unknown simultaneous unknown simultaneous interested important recommenda- same eligible effective effective more i effective subsequent prodromal vaccine-associated adverse preferred healthcare second outbreak second least older clinical g primary postexpo- visto age-appropriate • age- appropriate pregnant Preschool-aged older School-aged sure confirma- Commercial detect vaccine-induced false-negative pregnant other acte typical occupational clinic physician atypical epidemiologic typical such consid- valid other mild atypical similar severe allergic severe due immune immunosuppressive vacci- varicella-containing low-dose less alternate-day topical immunosup- pressive impaired humoral hypogam- humoral immunosuppressed severe cellular immunodefi- human immuno- higher older higher pregnant pregnant varicella-containing adverse preg- insert first second least other ergic maternal-fetal pregnant 800-986-8999 cal severe acute ill potential such such upper antibiotic other active antibody-containing immune whole red intravenous unknown potential antibody- same antibody-containing additional such least antibody-containing seronegative personal vaccina- personal such personal adverse severe allergic other live immu- primary other malignant lymphatic least Other immunosuppressive other clinical less less total other malignant lymphatic other clinical human immune high-dose equivalent more least other live viral lower intra- articular long-term alternate-day low short-acting systemic corticoste- immunosuppres- severe antiviral active other such 6-mercaptopurine immunosuppressive hematopoietic recipi- varicella-containing immune case-by-case relevant least reddi- human such anti-tumor preferable possible immune nant severe antiviral active such least least ive gener- high comparable antibody-containing antibody-containing other live recent other antibody-containing intra common adverse local such clinical local second local common similar mild self-limited varicella-like second present general- ized varicella-like second Most maculopapular common less wild-type such postherpetic live similar less wild- mild such postherpetic higher oral 5-12 additional separate same second same separate same elia-like most nerat hese largest clinical local common higher similar serious adverse serious adverse rare secondary few secondary clinical secondary wild several asymptomatic high such ormal recio varicella-containing frozen frozen lower urred same inadvertent varicella-containing off-site varicella-containing fragile off-site continuous Varicella-containing immuniza- acceptable other preservative other antiviral varicella- separate 800-982-7482 U.S.-licensed early investigational available investigational new severe investigational similar purified human high previous investigational n age-appropriate eligible neonatal less neonatal available available ngent live vari- healthy first preg- ear follow-up A-1 A-2 .A-9 Antibody-Live .. A-21 www.cdc.gov/vaccines/recs.schedules/child-schedule.htm Spanish black white Downloadable commercial black white Downloadable A-1 late catch-up 19-23 certain high-risk subsequent feasible separate equivalent //www.cdc.gov/vaccines/ significant adverse 800-822-7967 least previous • least last older certain underlying medical unknown possible more additional final fourth second least previous seasonal trivalent inactivat- HBsAg-positive least healthy older next well-child medical permissible combina- least seasonal final previous first maximum 2010-2011 seasonal older maximum final least • first acellular second least first fourth least third second least first valid least older pri- mary final pneumococcal conju- pneumococcal least younger persistent anatomic healthy human vac- 7-valent least 13-valent • single endemic epidemic age-appropriate single meningococcal medical meningococcal first American late recommended certain high-risk subsequent feasible separate equivalent significant adverse 800-822-7967 previous ovalent 2010-2011 seasonal unknown single catch-up single 13-valent pneumococcal additional toxoid-containing functional other • last cochlear least previ- pneumococcal least cervical last older certain cervical medical single functional anatomic 3-dose genital first third least first least first older older 3-dose incomplete 2-dose least • least persistent anatomic functional final fourth least previous least current • endemic epidemic minimum • meningococcal meningococcal second older seasonal second healthy least first valid medical older minimum least seasonal first American More Than catch-up minimum least first younger current younger final final final necessary first 12-14 current older younger older second younger previous older younger current younger final necessary final healthy older final healthy current current healthy high healthy previous older older younger first younger older least first younger older other important 3-dose minimum third 2-dose least maximum first older maximum final first second third acellular necessary fourth older unvaccinated older younger third final least second first second least final 13-valent pneumococcal healthy medical least fewer single certain underlying medical age-specific pneumococcal older certain underlying medical least last single functional anatomic final fourth least previous fourth necessary third older least previous first minimum minimum recom- imminent polio-endemic second minimum second least first valid older older acellular single other • 3-dose genital routine second third first minimum first second minimum second third third least first available 800-822-7967 vaccine-preventable local available 800-CDC-INFO 800-232-4636 other important 60-64 more previous other present medical occupational other significant available 800-822-7967 available 800-338-2382 avail- able 202-357-6400 available available 800-CDC- 800-232-4636 medical other infection3,6,12,13 human lympho- chronic elective persistent end-stage dose 1-time other medical occupa- tional other previous medical older other detailed complete //www.cdc.gov/vaccines/pubs/acip-list.htm American complete older nonpregnant high-risk medical Other inactivated older standard high-dose available acellular unknown 10-year feasible close younger direct older Other older recent uncertain incomplete 3-dose primary least third dose 6-12 second less one-time primary pregnant recent more administer second third recent less immediate immediate available single-antigen second medical high severe high child-care institutional correctional military nonpregnant international least healthcare pregnant atypical epidemiologic typical laboratory-confirmed first second 4-8 first catch-up potential sexual active consistent age-based active full genital abnormal positive previous genital effective sexual complete second 1-2 first third medical medical other live-virus medical medical single older previous chronic medical medical laboratory provider-diagnosed provider-diagnosed acceptable outbreak postsecondary educational unknown second first postsecondary educational unknown high pregnant laboratory and/or appropriate appropriate available chronic chronic chronic functional anatomic elective least chronic renal nephrotic possible Other long-term medical public invasive pneumococcal chronic renal nephrotic functional anatomic older less primary 2-dose meningococcal anatomic functional routine 2-dose Other single meningococcal unvaccinated first-year military meningococcal hyperendemic epidemic sub-Saharan dry local annual younger meningococcal older anatomic functional persistent chronic Other high available close personal regular international first high 2-dose more Single-antigen 2-dose 6-12 6-18 4-dose 21-30 active long-term monogamous previous current recent injection-drug other infectious end-stage renal Other chronic developmental international high available healthcare injection-drug correctional end-stage renal chronic nonresidential developmental 3-dose first third least second least first 4-dose other 3-dose 4-dose acceptable pneumococcal meningococcal live specific available A-8 next dose 1-4 HepB-2 1-2 2-17 HepB-34 6-18 Diphtheria-tetanus-acellular DTaP-2 DTaP-3 6-12 DTaP-4 15-18 DTaP-5 4-6 Hib-2 Hib-38 6-9 Hib-4 12-15 IPV-2 2-14 IPV-3 6-18 IPV-4° 4-6 Pneumococcal PCV-2 PCV-3 PCV-4 12-15 12-15 MMR-210 4-6 12-15 Var-210 4-6 12-23 6-18 2-49 Meningococcal MCV4-2 MPSV4-2 Tetanus-diphtheria-acellular Pneumococcal PPSV-216 11-12 available separate equivalent minimum oldest individual minimum equal greatest individual Japanese yellow available other available available younger other least least least first older fewer fourth third least previous RR-2 minimum varicella-1 most younger previous first inactivated influenza vaccine- specific minimum meningococcal high meningococcal meningococcal 1042-31 mild routine other nume primary tetanus-toxoid minimum previous tetanus-containing highest serious pneumococcal likely rapid pneumococcal pneumococcal minimum first third least first first older less third necessary single older acellular other catch-up mild previous final 3-dose last severe acute single-antigen least 12-15m 0- 2- 0- 1- HBsAg-positive newborn complete interchangeable unknown unvaccinated 4-6m 2-dose positive give HBsAg-positive •Give 4-6yrs previous possible same least severe • prior tetanus- previous •Give 1-time 11-12yrs young last previous •Give 1-time previous Special 1-2m 6-12m continuous more older l-time shock-like younger direct pregnant immediate previous acellular 6-18m 4-6yrs older certain final least previous least dose severe • sure current www.cdc.gov/vaccines/pubs/ACIP-list.htm other catch-up mild influenza healthy non-pregnant •Give first-time older yellow same least Previous younger chronic cardiovascular renal hepatic neurological/neuromuscular metabolic medi- current long-term severe previous protective specific antiviral least dose older • younger least older least prophy- yellow same least Previous • high-dose immunosuppressive cellular greater greater older severe state- specific vaccina- possible antiviral personal humoral hematologic solid congeni- tal long-term immunosuppressive symptomatic severe glob- same least ulin past thrombocytopenic personal first first •Give least dose dose least dose older yellow same least expo- sure healthy older other catch-up mild • 12-15m last previous interchangeable different necessary primary older previous 4-8wks 12-15m dose younger severe acute Pneumococcal severe feasible early younger older unvaccinated healthy high-risk least fewer least recent healthy older minimum 7-11m 12-23m least recent healthy other age-appropriate complete least recent high least recent least incomplete other age-appropriate complete least recent functional ana- tomic other cochlear previous functional chronic pulmonary renal cerebrospinal immunosup- pressive least final high-risk functional anatomic previous rec- severe other catch-up dose final older short different unknown acute acute chronic pre-existing gas- trointestinal severe older sub- older routine older other vacci- injectable non-injectable older close personal international high quadrivalent unvaccinated 2-55yrs older 11-55yrs functional persistent meningococcal hyperendemic epidemic permanent meningococcal vious older additional initial severe acute adverse available 3-dose 11-12yrs sched- early older genital least severe possible same older older mild anaphylactic available healthy cardiovascular renal hepatic healthy nonpregnant neurological/neuromuscular metabolic older standard-dose other high-dose following severe acute right given-LAIV previous same least protective specific vaccina- antiviral older younger chronic other chronic pulmonary chronic cochlear special social local public authori- highest fatal pneumococcal anatomic functional dis- previous unknown anaphylactic l-time severe dose high- fatal pneumococcal rapid highest dose infec- multiple myelo- chronic renal nephrotic immunosuppressive www.cdc.gov/vaccines/pubs/ACIP-list.htm sure current older least labora- first • such unpaid other post- high educational international healthcare acceptable dose pregnant susceptible give long- immunosuppressive following live yellow greater equal same least severe susceptible thrombocytopenic same dose anaphylactic dose following live • high-dose immunosuppressive primary yellow cellular same least greater equal 2-dose severe dose 4-8 susceptible specific possible antiviral 4-8 older older unvaccinated primary anaphylactic primary 1-2m least tetanus- diphtheria-toxoid-containing one-time con- •Give severe immediate primary •Guillain-Barré inter- ous tetanus-toxoid-containing younger previous Unstable neurologic older previous younger health- tetanus- and/or pregnant direct older anaphylactic severe chronic non-injecting com- potential experimental private appropriate older close personal international high fol- least least younger recent older recent im- alternative 21-30d anaphylactic active long-term monogamous severe least renal least healthcare public least long-term correctional certain international chronic endemic appropriate HBsAg-positive initial same unvaccinated re- genital least least Overall be- tween possible same anaphylactic severe older 1-time previous following live given-MMR yellow same least anaphylactic severe specific possible antiviral anatomic functional me- ningococcal hyperendemic epidemic menin- anaphylactic severe acute adverse available •Give initial anatomic functional initial other 1st-3rd col- possible younger older permanent contra- unique infor- older com- primary vacci- wild-type likely endemic high severe immune measles- varicella-containing varicella-containing units/10 60-200 thrombocytopenic thrombocytopenic syncytial negligible 80-100 300-400 correct antibody-containing entire additional immune antibody-containing asymptomatic symptomatic other immunosuppressive investigational similar purified human high 3-dose dose anti-HBs serologic 1-2 injectable influenza live serologic serologic prior primary 3-dose 1-time younger direct on-the-job fecal equivocal nonimmune 3-dose appropriate 0- 1- 6-month live first 1-2 least live anti-HBs least positive acceptable further serologic anti-HBs negative unpro unvaccinated 3-dose anti-HBs 1-2 and/or same anti-HBs positive vac anti-HBs negative susceptible probable parenteral possible physician positive positive Anti-HBs primary tetanus/diphtheria- 1-2 original feasible younger direct anti-HBs negative l-time susceptible younger medical younger annual permanent contraindica- influenza non-pregnant healthy younger injectable older immunosuppressed medical additional specific official www.cdc.gov/vac- immune • X-linked common variable live oral uncertain humoral immune severe selective Other live safe effective complete live ineffective cell-mediated humoral most Wiskott-Aldrich ataxia- immune effective safe granulomatous effective safe effective Other available Live bacterial yellow general severe granulomatous age-based chronic granulomatous clinical inactivated effective immunosuppressive bacterial immune effective renal effective Other available Symptomatic yellow available Yellow yellow bacterial yellow general dialysis-based allergic previous allergic previous severe less • severe other gastrointestinal previous attributable identifi- able previous previous severe previous toxoid-containing arthus-type previous toxoid-containing least last tetanus-toxoid unstable uncontrolled progressive encepha- higher higher previous shock-like hypotonic hyporesponsive epi- previous previous previous allergic previous severe previous toxoid- arthus-type previous toxoid-containing least last tetanus-toxoid allergic previous severe younger allergic previous severe severe allergic severe previous toxoid-con- severe allergic previous allergic previous severe antibody-containing severe • thrombocytopenic solid congenital immunodefi- long-term immunosuppressive allergic previous severe solid congenital long-term immunosuppressive previous severe specific specific possible antiviral severe injectable allergic previous severe previous uated allergic previous reactive recent chronic medical severe previous specific antiviral vac- previous severe severe allergic previous poly- allergic previous severe specific possible antiviral specific vac- chil- underlying neurologic case-by-case preterm chronological HBsAg-positive same admin- same least immunosuppressive more daily > tious American same least urgent www.cdc.gov/vac- allergic previous attributable identifiable previous severe previous toxoid-containing arthus-type previous toxoid-containing last tetanus toxoid-containing unstable progressive severe papilloma- allergic previous allergic previous severe solid congenital long- severe antibody-containing specific thrombocytopenic previous severe solid congenital long- immunosuppressive previous severe specific specific possible antiviral injectable severe previous uated allergic previous chronic medical severe previous specific avoid antiviral severe allergic previous allergic previous severe severe allergic previous severe allergic previous poly- allergic previous severe specific possible antiviral specific same adminis- same least immunosuppressive more daily same least urgent p.40-41 acellular acellular acellular 4-6 15-18 2-dose primary 3-dose primary pediatric 3-dose routine 4-dose rapid older multidose seasonal 3-dose Japanese older 2-dose complete 3-dose complete 2-dose older older acellular Vaccine-Preventable uniform American final mixed ulmonolololoQY111- Acel-Imune Measles-Smallpox b-CAPSA-1 live 1988-2007 live 1969-79 1949-55 1944-2008 live 1981-90 live 1974-78 live 1965-76 1998-2002 live oral live oral 1949-55 Pfizer-Vax live 1965-70 polysaccharide 23- Pnu-Imune 1977-83 1988-91 1956-65 1959-68 1908-57 1998-99 live 1969-72 live 1963-71 1945-54 1962-77 1959-68 1959-65 DTP-Polio 1952-64 inactive necessary pharmaceutical vac- other immunologic suitable further pharma- ceutical reasonable manu- human oral green nutrient residue Ethylenediamine-tetraacetic inactiva- stabilizier DTaP-Hep Japanese solvent Japanese oral nutrient most most cellular oral residue Japanese residue antibacterial red phenolsulfon- dihydro- most agent viral octyl viral octoxynol-10 octyl- phenoxypolyethoxyetha- p-isooctyphenyl nutrient viral most phosphate precise con- con- Japanese single-dose pre- nutrient stable unspecified combi- fertilized Yellow YF-Vax Stainer-Scholte con- DTP-Hep human fetal essential con- fetal human green Japanese meningococcal fetal DTP-Hep Synthetic/semi-synthetic Engerir-B polysac- joint 48:563-565 viral 1998:93:97-107 31:1387-92,1397-1401 human 1965:37:614-636 human 168-170 viral harmful 112:1394-1401 final table 2-Phenoxyethanol 2-Phenoxyethanol 2-Phenoxyethanol 2-Phenoxyethanol multi-dose single-dose 2-Phenoxyethanol 2-Phenoxyethanol a-Tocopheryl multidose single-dose multidose 2-Phenoxyethanol Japanese 10-dose Ethylenediamine-Tetraacetic 2-Phenoxyethanol 2-Phenoxyethanol oral Ethylenediamine-Tetraacetic equivalent thimerosal-free biological severe anaphylactic natural potential allergic other anaphylactic dry natural best Vial vial vial sanofi sanofi multi-dose single adult/pediatric preservative free preservative free multi-dose single vial multi-dose single multi-dose single multi-dose single commercial military multi-dose single equivalent decreased equivalent thimerosal-free biological foreign preventable other specific other //www.immunize.org/izpractices/p5120.pdf comprehensive complete Italian Norwegian liet acellular whole whole whole Chemo-Sero-Therapeutic whole military toxoid whole live oral military acellular same pediatric pediatric Tick-borne virosomal live recombinant whole Tick-borne whole whole same whole live whole whole whole whole pediatric live live whole whole live live live whole 23-valent live oral whole culture-based oral acellular acellular 23-valent live oral oral oral 7-valent live live 23-valent acellular acellular live live live live live live live live Pneumococcal 23-valent 10-valent T-Vaccinol paratyphoid oral live acellular acellular live acellular live oral viral whole-cell whole-cell live live live live live live live pediatric live oral live oral live C-1 .C-2 C-4 C-5 C-6 6-7 important back-up household-style commercial-style dormitory-style separate exterior free-standing separate free-standing newest longest shortest extra cold other ice-filled cold clinic time- electrical adequate undamaged affected detailed general local least monthly large stable open earliest electrical protected electrical perishable immedi- auxiliary other local 37-7 right 35-F-toek neceptable new upper acceptable acceptable current unacceptable tem- next unacceptable acceptable acceptable next current unacceptable unaccept- able cold unacceptable clinic 4-6 • 243-8832 •VFC pertussis-containing 35°F-46°F 20-8°C Irreversible 35°F-46°F 20-8°C Irreversible 35°F-46°F 20-8°C lyophilized 35°F-46°F 2-8°C Irreversible 35°F-46°F 20-8°C recommended Meningococcal 35°F-46°F 20-8°C 35°F-77°F 20-25°C light 35°F-46°F 20-8°C 35°F-77°F 20-25°C Irreversible 35°F-46°F 20-8°C 35°F-46°F 20-8°C 35°F-46°F 20-8°C 68°F-77°F 200-25°C 35°F-77°F 20-25°C 35°F-77°F 20-25°C vaccine //eziz.org/PDF/IMM-940 //www.eziz.org/PDF/IMM-962 //www.eziz.org/PDF/IMM-965 //www.eziz.org/PDF/IMM-963 StoringVaccines-Refrig-only.pdf //www.eziz.org/PDF/IMM-966 Vaccines-freezer.pdf //www.immunize.org/catg.d/p3039.pdf short-term //www.eziz.org/PDF/IMM-983Transporting 800-533-5899 888-435-8633 877-246-8472 866-475-8222 877-633-4411 800-637-2579 800-244-7668 800-934-5556 800-822-2463 .. .D-21 critical successful general professional right right correct appropriate competency-based new validate //www.eziz.org/PDF/IMM-694.pdf temporary short such new new new active //www.eziz.org/PDF/IMM-686ES.pdf next new Many other //www.immunize.org/handouts/screening-vaccines.asp first powerful vaccine-preventable other reliable open safe additional important unavoidable least stressful possible positive facial soft small sick uncomfortable //www.eziz.org/PDF/IMM-720ES.pdf aware sure aware supportive such common needlestick subjective previous important previous Evidence-based age-appropriate non-aspirin-containing prophylactic non-pharmacologic such effective deep sweet-tasting Several young younger small few sugary short-acting inexpensive young painful last multiple moderate older older intramuscular other insufficient evidence-based separate other vulnerable subcutaneous intramuscular more other available critical alcohol-based antiseptic infectious open needlestick appropriate follow-up accidental medical critical separate parenteral 1-mL 3-mL safety-engineered needle-shielding needle-free injectable clinical clinical optimal needle individual patient available viscous fine 22-25 Needle-Free new needle-free needlestick needle-free last available normal Several freeze-dried specific wrong valid single necessary //www.eziz.org/PDF/IMM-897.pdf vial possible many Single-dose manufacturer-filled single-dose inactivated same clinic single-dose clinic difficult single-dose same manufacturer-filled sterile single separate single vial necessary full 10-dose clinical practical theoretical local adverse oral U.S.-licensed oral oral other oral routine 4-week minimum other nasal special equal upright other other possible low-level severe protective such hematopoietic Other higher medical likely pregnant older Subcutaneous subcutaneous younger upper older necessary upper subcutaneous 5/8-inch 23- 25-gauge needle fatty light several dry subcutaneous meningococcal intramuscular Many local proper critical anterolateral upper neural vascular large needle necessary less safety-engineered femoral middle femoral intramuscular intramuscular -Deltoid 22- 25-gauge needle subcutaneous familiar needle adipose large potential sciatic antimicrobial anatomic important intramuscular subcutaneous 1-inch intramuscular older 1-inch 22-25-gauge first needle adequate flat needle 90-degree lateral superior posterior superior greater anterior superior upper greater lateralis anterolateral least 1-inch deltoid adequate 5/8-inch flat needle needle deltoid 22-25 5/8- 1-inch young 5/8- 1-inch general older 1-inch obese 1/2-inch helpful appropriate anterolateral alternative 1- 14/4-inch most older Older intramuscular anterolateral less 5/8- 1-inch sufficient intramuscular deltoid 90-degree 130-152 60-70 1-inch sufficient 152-200 70-90 152-260 70-118 1- 1/2-inch more 1/2-inch subcutaneous acceptable pediatric geriatric needle light several dry //www.aimtoolkit.org/adolescents/immun/Injectable //www.aimtoolkit.org/adolescents/immun/TipsForImmunizingAdolescents.pdf //www.aimtoolkit.org/adult/Injectable_Adult_121709.pdf //www.eziz.org/PDF/IMM-685.pdf multiple single different anatomic desirable younger single preferred greater older more intramuscular possible local tetanus-containing different possible separate anatomic medical same anatomic different familiar reasonable similar such 23-gauge same same exaggerated local certain hazardous excessive local other smaller divided full smaller standard partial parenteral needle other intramuscular other anterolateral valid other more life-threatening anaphylactic familiar familiar facial available detailed immediate additional medical permanent medical parent/guardian permanent medical adverse serologic vaccine-preventable additional important American other ineffective vulnerable other possible same different other multiple current available needle easy shortest sound-alike look-alike other other same important potential complete available available //www.immunize.org/shop/toolkit appropriate 1-12 anterolat- eral thigh older anterolat- eral needle 2-dose thigh 1-2 mL 1-144 5/8-1 thigh deltoid 5/-1 anterolateral thigh older 5/8-1 less lbs 1-1/2 subcutaneous subcutaneous subcutaneous complete particular 1-142 vial 1-14 1-142 1-1/2 * 1-142 1-1/2 1-142 * 1-1972 * vol- entire single reconstituted intramuscular sufficient sufficient 1-14 lbs 70-90 weigh- subcutaneous complete particular potential adverse adverse careful trivial various cold analgesic antipruritic adhesive direct patient light-headedness visual flat several tight open present present gradual severe detailed abdominal cardiovascular available oral small large extra-large one-way extra on-site gradual abdominal cardiovascular medical on-call second primary aqueous maximum single intramuscular maximum dose cardiopulmonary necessary flat difficult adequate low present vital medical other relevant clinical injectable intramuscular injectable lbs 15-24 1-6 kg 7-18 7-11 19-36 11-14 37-48 14-17 49-59 17-19 19-23 older 5-7 8-10 11-12 50-100 medical clinic American Red American 64-66 Pharmacy-Based potential adverse adverse careful trivial various cold analgesic antipruritic adhesive direct patient light-headedness visual flat several tight open present present gradual severe abdominal cardiovascular detailed small large extra-large least one-way available solu- extra second on-site gradual abdominal cardio- medical on-call second primary aqueous single systemic intramuscular single cardiopulmonary necessary flat difficult adequate low present vital medical other relevant clinical American Pharmacy-Based 2001:80-82 medical clinic federal current complete current more alterna- tive serious many Most adverse self-limited rare devas- safe possible important parents/legal objective mak- adverse common standardized objective ben- adverse current available pneumococcal poly- various interna- tional recom- federal alternative routine through-6-month pneumococcal ro- routine other pediatric acceptable perma- local individual other direc- recent inactive Japanese JE-Ixiaro Multi-vaccine undergo intense prop- mi- legal health- parent/le- gal legal NCVIA-covered tered parent/legal representa- current available patient mandatory ru- pneumococ- cal meningococcal human parent/legal informa- past available available local trivalent pneumococcal meningococcal relevant current legal such other minor such relevant legal single long-term relevant visual oral permanent medical 300aa-25 permanent medical permanent legal additional applicable Current live Multi-Vaccine routine pneumococcal available many other camera-ready available 300aa-26 current available current available camera-ready new Text compatible screen-reader vision-impared many available available Japanese Korean Laotian Serbo-Croatian medical informed appropriate separate legal good appropriate legal legal legal other legal representative adverse new new final new adverse previous visual oral least available compatible old obsolete adverse current multiple identical different adverse adverse clinical traditional Fletch-Kincaid 10th useful several low-literacy racial ethnic native easy positive legal present school-based adolescent legal medical permissible single entire acceptable first legal complete possible approximate additional initial legal original additional earlier next original additional medical additional additional significant adverse earlier adverse previous medical single-vaccine optional such appropriate first individual medical clear individual older older same 12-month old 4-year old catch-up primary routine pediatric single-vaccine individual new single same other important adverse certain patient up-to-date important other such routine Related Vaccine-Related common legal federal certain updaiD| new More new other upcorrung Other Other national most describe such serious such important new Most parent/guardian significant adverse online On-Line e-mail 800-822-7967 877-721-0366. e-mail 800-822-7967 877-721-0366. anaphylactic applicable additional anaphylactic applicable additional anaphylactic applicable additional applicable additional 7-30 viral applicable additional non-immunodeficient immunodeficient vaccine-associated applicable viral non-immunodeficient vaccine-associated applicable applicable additional anaphylactic applicable additional anaphylactic applicable additional additional additional interval additional Pneumococcal 7-valent 13-valent additional additional additional interval additional additional reportable 300aa-25 significant unexpected certain adverse no-fault traditional individual vaccine-related physician medical special civil first legal disabled legal eligible more human meningococcal easier severe other Such medical comprehensive toxoid-containing anaphylactic 0-4 2-28 applicable antigen-containing anaphylactic 0-4 applicable anaphylactic 0-4 5-15 applicable virus-containing applicable virus-containing 7-30 0-6 applicable acute live non-immunodeficient 0-30 immunodeficient 0-6 applicable viral 0-30 non-immunodeficient 0-6 applicable applicable anaphylactic anaphylactic 0-4 applicable 0-4 applicable applicable applicable applicable applicable new applicable routine trivalent meningococcal human Vaccine-Preventable 1962-2009 1950-2009 paralytic paralytic +Vaccine-associated reportable other other invasive notifiable 1025-39 :856-69 Reportable 1950-2003 respective 20th 20th paralytic est < + 1704-1716 invasive 1-25 1962-2009 measles-containing national more measles-containing more measles-containing more 2-year-old represent 19-35 month-old available more annual present 800-232-4636 800-CDC-INFO Spanish vaccine-preventable single vaccine-preventable related e-mail //www.cdc.gov/vaccines/vac-gen/safety/default.htm specific other vaccine-preventable main “ such online latest downloadable other //www.cdc.gov/vaccines/ed/curric-brocnhre.htm Other many good few free other useful //www.chop.edu/service/vaccine-education-center/home.html current separate other useful other credible 334-206-5023 334-206-2044 303-692-2363 303-691-6118 907-562-7802 860-509-7945 602-364-3630 602-364-3285 302-744-1181 302-739-2555 state.de.us 501-661-2795 501-661-2300 202-576-9336 202-576-6418 510-620-3737 510-620-3774 850-922-4195 404-463-6355 404-344-5635 dhr.state.ga.us 808-586-8328 808-586-8302 785-296-6510 / 502-564-4760 208-334-5942 208-334-4914 504-838-5300 504-838-5206 217-785-1455 217-524-0967 6-A 317-233-7010 317-233-9245 50319-0075 515-281-7301 / 800-831-6292 idph.state.ia.us 207-287-3746 207-287-8127 410-767-6679 410-333-5893 617-983-6823 617-983-6962 517-335-8159 517-335-9855 775-684-3209 775-687-7596 651-201-5507 651-201-5501 603-271-4482 603-271-3850 601-576-7751 601-576-7686 08625-0369 609-588-7520 609-588-3642 87502-6110 573- 526-5165 573-526-5220 505-827-2463 505-827-1741 59601-2951 12237-0627 518-473-4437 518-474-1495 406-444-0065 406-444-2920 68509-5007 27699-1917 402-471-2139 402-471-6425 919-715-6781 nebraska.gov beth.rowe-west 803-898-0933 803-898-0326 58501-5044 701-328-2499 nd.gov @ 614-466-4643 614-728-4279 605-773-5323 605-773-5509 10th 405-271-4073 405-271-6133 615-741-7507 615-532-8526 971-673-0278 lorraine.Duncan 717-787-5681 717-705-5513 512-458-7607 512-458-7343 801-538-9440 utah.gov 802-852-4185 802-865-7701 02908-5097 401-222-5291 401-222-1442 804-864-8055 804-864-8089 608-266-1339 608-267-9493 307-777-6001 307-777-3615 360-236-3568 360-236-3590 25301-3715 304-558-6426/ 304-558-6335 505-248-4374 505-248-4393 American 011-684-633-7223 584-633-5379 / 670-236-8700 671-735-7143 671-734-1475 680-488-6750 680-488-4800 692-625-8457 692-625-4543 787-274-6807 @ ntamar.net 691-320-2619 691-320-5263 340-776-1155 340-774-5813 312-746-6120 312-746-6388 chavez-torres_m 713-794-9474 713-558-2468 212-676-2248 212-676-2258 210-207-8794 210-207-8882 Vivian 215-685-6603 215-685-6806 